

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number  
WO 2005/049641 A2

(51) International Patent Classification<sup>7</sup>:

C07K 14/19

(74) Agent: HØIBERG A/S; St. Kongensgade 59 A, DK-1264 Copenhagen K (DK).

(21) International Application Number:

PCT/DK2004/000803

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

19 November 2004 (19.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2003 01726	21 November 2003 (21.11.2003)	DK
60/524,617	25 November 2003 (25.11.2003)	US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHROTZ-KING, Petra [GE/DK]; Brobæklynden 115, DK-5260 Odense SØ (DK). SKAARUP, Crawford, Janne [DK/DK]; Svendborgvej 48, DK-5772 Kvrndrup (DK). NYBORG, Nielsen, Pia [DK/DK]; Hverringevej 13, DK-5230 Odense M (DK). PROKHOROVA, Tatyana, A. [BY/DK]; Ablegryden 9, DK-5592 Ejby (DK).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/049641 A2

(54) Title: SURFACE-LOCATED CAMPYLOBACTER JEJUNI POLYPEPTIDES

(57) Abstract: The present invention relates to surface-located polypeptides of *Campylobacter jejuni* and their use in vaccination against *Campylobacter*. The invention furthermore relates to the use in vaccination of polynucleotides, expression vectors, recombinant viruses or recombinant cells expressing these surface-located polypeptides. Moreover, the invention relates to the use of antibodies against the surface-located polypeptides for anti-*Campylobacter* therapy. Finally, methods for detection of *Campylobacter* and for identifying anti-*Campylobacter* agents through the surface-located polypeptides is disclosed.

**Surface-located *Campylobacter jejuni* polypeptides**

This application is a non-provisional of U.S. provisional application Serial No. 60/524,617, filed November 25, 2003, which is hereby incorporated by reference in 5 its entirety. All patent and non-patent references cited in this application are hereby incorporated by reference in their entirety.

**Field of the invention**

The present invention relates to cell-surface-located polypeptides of *Campylobacter jejuni* and their use in immunisation against *Campylobacter* infection, in diagnosis of 10 *Campylobacter* and in identification of compounds with anti-*Campylobacter* activity.

**Background of the invention**Occurrence of *Campylobacter* infections

15 *Campylobacter*, a Gram-negative microaerophilic bacterium, was first identified as a human pathogen in 1973. It has since become the most common bacterial cause of diarrhoeal illness in the developed world, causing more disease than the more traditionally recognised food-borne pathogens, *Shigella* species (spp). and *Salmonella* spp. combined. Of the different disease-causing *Campylobacter* strains, *C. jejuni* is 20 the most important, being responsible for 99% of cases of campylobacteriosis. At a global level, surveillance has indicated a steady rise in the number of reported cases of campylobacteriosis since this organism was first recognised as a pathogen. Indeed, the World Health Organisation now recognises bacteria causing campylobacteriosis to be the most important agents of enteritis in the world. International public 25 health officials estimate that *C. jejuni* alone causes 400 to 500 million cases of diarrhoea world-wide each year, and it is the number one food-borne pathogen in the U.S. Recent data for the year 2000 illustrate the significance of *Campylobacter* with respect to other more publicised causes of food borne illness. *Campylobacter* accounts for more cases, hospitalisations and deaths than *Salmonella* or *E. coli*-mediated food-borne illnesses. Amongst the data set, *Campylobacter* accounts for 30 greater than 55% of cases and 33% of hospitalisations.

Symptoms of *Campylobacter* infections

Diarrhoea is the most consistent and prominent manifestation of campylobacteriosis. 35 It is often bloody. Typical symptoms of *C. jejuni* infection also include fever, nausea,

vomiting, abdominal pain, headache, and muscle pain. A majority of cases are mild and do not require hospitalisation and may be self-limited. However, *C. jejuni* infection can be severe and life-threatening. Death is more common when other diseases (e.g. cancer, liver disease, and immunodeficiency-related diseases) are present.

5 Children under the age of five and young adults aged 15-29 are the age groups most frequently affected. The incubation period (the time between exposure on onset of the first symptom) is typically two to five days, but onset may occur in as few as 2 days or as long as 10 days after ingestion. The illness usually lasts no more than one week; however, severe cases may persist for up to three weeks (CDC

10 Guidelines for confirmation of food-borne disease outbreaks. MMWR, 1996; 45:59).

#### Long-term consequences of Campylobacter

Campylobacter infection can sometimes have long-term consequences. Some patients may develop a disease, called Guillain-Barré syndrome, that affects the nerves of the body following campylobacteriosis. Although rare, it is the most common cause of acute generalised paralysis in the Western world. It begins several weeks after the diarrhoeal illness in a small minority of Campylobacter patients. It occurs when a person's immune system generates antibodies against components of Campylobacter and these antibodies attack components of the body's nerve cells

20 because they are chemically similar to bacterial components.<sup>1</sup> Guillain-Barré syndrome begins in the feet and spreads up the body. Prickling sensations give way to weakness that may lead to paralysis. It lasts for weeks to months and often requires intensive care. Full recovery is common, however patients may be left with severe neurological damage. Approximately 15% of Guillain-Barré patients remain bedridden or wheelchair-bound after one year. It is estimated that approximately one in

25 every 1000 (0.1%) reported campylobacteriosis cases leads to Guillain-Barré syndrome. As many as 40% of Guillain-Barré syndrome cases in the UK occur following campylobacteriosis.<sup>2</sup>

Miller Fisher Syndrome is another, related neurological syndrome that can follow campylobacteriosis and is also caused by immunologic mimicry.<sup>1</sup> In Miller Fisher syndrome, the nerves of the head are affected more than the nerves of the body.

Another chronic condition that may be associated with Campylobacter infection is an arthritis called Reiter's syndrome. This is a reactive arthritis that most commonly affects large weight-bearing joints such as the knees and the lower back.

It is a complication that is strongly associated with a particular genetic make-up; persons who have the human lymphocyte antigen B27 (HLA-B27) are most susceptible.

5 In addition, *Campylobacter* may also cause appendicitis or infect the abdominal cavity (peritonitis), the heart (carditis), the central nervous system (meningitis), the gallbladder (cholecystitis) the urinary tract, and the blood stream.

References:

1. Ang CW et al. (2001) *Infect Immun.* 69(4):2462-2469.
2. Rees et al. (1995) *N Engl J Med* 333:1374-1379.

10

Treatment of campylobacteriosis

15

Patients with campylobacteriosis should drink plenty of fluids as long as the diarrhoea lasts in order to maintain hydration. Antidiarrhoeal medications such as loperamide may allay some symptoms. *Campylobacter* is usually a self-limited illness, but when it is identified, specific treatment with antibiotics is indicated, as treatment may shorten the course of the illness. In more severe cases of gastroenteritis, antibiotics are usually begun before culture results are known. Macrolide antibiotics (erythromycin, clarithromycin, or azithromycin) are the most effective agents for *C. jejuni*. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, gatifloxacin, or 20 moxifloxacin) can also be used.

20

However, resistance of *Campylobacter* to antimicrobial agents has been reported in many countries and is on the rise (Pedington and Kaneene (2003) *J. Vet. Med. Sci.* 65(2):161-170). Quinolone-resistance is on the rise in Europe, Asia and the US. The increase of resistance is at least partially related to the use of antibiotics in poultry feed (Smith et al. (1999) *N Engl J Med* 340:1525-1532).

Novel strategies for the treatment, prevention and diagnosis of *Campylobacter*

30

Because of the increase in incidence and the widespread occurrence of resistance, there is a considerable need for the development of new effective products for the treatment and prevention of *Campylobacter* infections. On one hand, due to the occurrence of resistance, there is a need for novel anti-*Campylobacter* compounds. On the other hand, observational and experimental studies have provided evidence of acquired immunity developing in humans, lending support to the concept of vaccine development, in particular for risk groups (Scott and Tribble (2000) 35 In: *Campylobacter*, 2<sup>nd</sup> ed. Ed. by Nachamkin and Blaser, American Society for Mi-

crobiology, pp. 303-319). In addition, there is a need for novel rapid and reliable methods for diagnosis of *Campylobacter* infections.

These objectives can be accomplished through the identification and use of suitable *Campylobacter jejuni* polypeptides that can function as targets, i.e. targets for the immune system and/or for antibodies, targets for cytotoxic inhibitors, or targets for indicator moieties in diagnosis.

### **Summary of the invention**

The present application relates to surface-located polypeptides of *Campylobacter jejuni*. In the context of this application, a 'surface-located' polypeptide is defined as a polypeptide which is at least partially (i.e. part of the polypeptide chain and/or part of the population of polypeptide molecules) localised outside the outer membrane of a *Campylobacter jejuni* cell. Thus, a surface-located polypeptide is a polypeptide which is fully or partially exposed to the space outside the outer-membrane. Surface-located polypeptides furthermore include all polypeptides or polypeptide fragments that can be identified in fractions obtained by low-pH surface-protein extraction as described herein.

Surface-located polypeptides are attractive targets for antibacterial therapy and/or diagnosis of bacterial infection, since the exposure of such polypeptides to the extracellular space means that compounds that interact with these polypeptides (e.g. compounds used to prevent, treat or diagnose bacterial infections) often do not need to enter or pass the outer membrane to be effective.

The determination of cell-surface localisation of a *Campylobacter jejuni* polypeptide can at present only be done experimentally and not by bioinformatics, as no common sorting signals or motifs are known for this localisation. It is possible to predict with some degree of certainty whether or not polypeptides enter the periplasm, but no general motif has been identified for surface-localisation of polypeptides, and therefore it is not possible to predict from the sequence alone whether any given periplasmic (or non-periplasmic) polypeptide will be transported to the surface. The number of confirmed surface polypeptides is relatively low in *Campylobacter jejuni* and includes mostly flagella structural proteins and a small number of non-flagella related surface proteins, such as PEB1-4.

The inventors have identified 51 different polypeptides in cell-surface fractions of *Campylobacter jejuni*. The method that was employed identifies polypeptides that are expressed at a relatively high level. The combination of being surface-

exposed and being present in relatively high amounts makes these polypeptides highly suitable as targets for antibodies and thus for use in passive or active immunisation/vaccination.

5 Accordingly, in a first aspect, the invention relates to a composition comprising

- a polypeptide which comprises a sequence selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,  
or
- a polynucleotide comprising a sequence encoding said polypeptide,  
or
- an expression vector comprising a sequence encoding said polypeptide,  
or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,  
or
- an antibody capable of binding said polypeptide,  
for use as a medicament.

10

20 In a further main aspect, the invention relates to the use of

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- 25 - an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

for the preparation of a medicament for the immunisation of an animal or human being against *Campylobacter*, preferably *Campylobacter jejuni*, infections.

30 Furthermore, the invention relates, in a main aspect, to the use of an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:1-51 for the manufacture of a medicament for the treatment or prevention of *Campylobacter*, preferably *Campylobacter jejuni*, infections in an animal or human being.

35

Fifteen of the 51 surface-located polypeptides that were identified (SEQ ID NO:37-51) have previously been described amongst more than 36,000 other loci as hits in homology searches using essential genes from other bacteria, see WO 02/077183.

5 WO 02/077183 does not describe an identification of the subcellular localisation of the identified polypeptides nor a determination of their expression levels.

In a further main aspect, the invention relates to an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:1-36.

10

In an even further main aspect, the invention relates to an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:37-51 and capable of binding an intact *Campylobacter jejuni* cell.

15

In a further aspect, the invention relates to methods of raising the above antibodies of the invention.

The combination of being surface-exposed and being present in relatively high

amounts also makes the 51 polypeptides identified by the inventors highly suitable

20 as targets for diagnosis of campylobacteriosis, allowing detection of intact cells with

high sensitivity. Thus, in a further main aspect, the invention relates to methods for

detecting *Campylobacter jejuni* or parts thereof, using indicator moieties capable of recognising the cell-surface located polypeptides described herein.

25 In addition, the surface-localisation of the 51 polypeptides makes them suitable as

targets for inhibitors. Such inhibitors may be bactericidal or bacteriostatic or prevent

interaction of *Campylobacter jejuni* with the host organism (virulence). Thus, in a

further main aspect, the invention relates to methods for identifying inhibitors of the cell-surface located polypeptides described herein.

30

### Definitions

- Vaccine - is used to indicate a composition capable of inducing a protective immune response against a microorganism in a human being or animal.
- Protective immune response – is used to indicate an immune response (humoral/antibody and/or cellular) inducing memory in an organism, resulting in the

35

infectious agent, herein *Campylobacter jejuni*, being met by a secondary rather than a primary response, thus reducing its impact on the host organism.

- Polypeptide – unless specified otherwise, the term ‘polypeptide’ when used herein can also refer to a variant or fragment of a polypeptide. Preferred polypeptides are antigenic polypeptides.  
5
- Fragment – is used to indicate a non-full length part of a polypeptide. Thus, a fragment is itself also a polypeptide.
- Variant – a ‘variant’ of a given reference polypeptide refers to a polypeptide that displays a certain degree of sequence identity to said reference polypeptide but  
10 is not identical to said reference polypeptide.
- Antigen / antigenic / antigenicity / immunogen / immunogenic / immunogenicity – all refer to the capability of inducing an immune response.
- Immunogenic carrier – refers to a compound which directly or indirectly assists or strengthens an immune response.
- 15 - Expression vector - refers to a, preferably recombinant, plasmid or phage or virus to be used in production of a polypeptide from a polynucleotide sequence. An expression vector comprises an expression construct, comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and which is operably linked to the elements of (1); and (3) appropriate transcription initiation and termination sequences.  
20
- Binding partner - of a polypeptide refers to a molecule that can bind to said polypeptide. Such binding can be indirect, through another molecule, but is preferably direct. A binding partner can be any type of molecule, such as e.g. small hydrophobic molecules or e.g. a cellular or extracellular macromolecule, such as a protein, a carbohydrate or a nucleic acid. Preferred types of binding partners include antibodies, ligands or inhibitors.  
25
- Plurality - the term ‘plurality’ indicates more than one, preferably more than 10.
- 30 - Indicator moiety - the term ‘indicator moiety’ covers a molecule or a complex of molecules that is capable of specifically binding a given polypeptide and/or cell, and is capable of generating a detectable signal. Preferably, the indicator moiety is an antibody or comprises an antibody molecule. Thus, a preferred indicator moiety is an antibody coupled to or in complex with a detectable substance.

- Host-derived molecule or host molecule - refers to a molecule which is normally found in a host organism that can be infected with *C. jejuni*. A host-derived molecule is preferably a host polypeptide, preferably a human polypeptide.
- Antibody - the term 'antibodies' when used herein is intended to cover antibodies as well as functional equivalents thereof. Thus, this includes polyclonal antibodies, monoclonal antibodies (mAbs), humanised, human or chimeric antibodies, single-chain antibodies, and also binding fragments of antibodies, such as, but not limited to, Fab fragments,  $F(ab')_2$  fragments, fragments produced by a Fab expression library, anti-idiotypic antibodies, hybrids comprising antibody fragments, and epitope-binding fragments of any of the these. The term also includes multivalent, multispecific, such as bispecific antibodies and mixtures of monoclonal antibodies.
- Dissociation constant,  $K_d$ , is a measure to describe the strength of binding (or affinity or avidity) between macromolecules, for example an antibody and its antigen. The smaller  $K_d$  the stronger binding.
- Isolated - used in connection with polypeptides, polynucleotides and antibodies disclosed herein 'isolated' refers to these having been identified and separated and/or recovered from a component of their natural, typically cellular, environment. Contaminant components of the natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. Polypeptides, polynucleotides and antibodies of the invention are preferably isolated, and vaccines and other compositions of the invention preferably comprise isolated polypeptides or isolated polynucleotides or isolated antibodies.

### **Detailed description**

#### **Figures**

30 Figure 1. Sera from four randomly selected mice per antigen from experiments ACE003b and ACE003c were diluted 1:2000 and tested on Western blot against whole cell campylobacter lysate (B, D) or 100 ng of recombinant protein (A, C). Molecular weight marker proteins MW in kD: 97, 64, 51, 39, 28, 19, 14.

Figure 2. An example of antibody titer determination. Serum from a randomly selected mouse (one per antigen) from experiments ACE003b and ACE003c taken on day 21 (preceded by immunization on days 1 and 14) was serially diluted and Western blot was performed on corresponding recombinant protein (100ng/spot).

5

Figure 3. Results of mouse oral challenge. Five experiments including different combinations of antigens and controls were performed as listed below:

Alum negative control in squares, antigen in triangles, except for ACE017, there the antigen is also in triangles, but the positive control is glycine eluate (Rombus) and

10 the negative control is CBP (see below) and is resembled by squares.

Experiment name	Antigens used
ACE003b	Cj0092, Cj0143c, Cj0420, Cj0772c, alum
ACE003c	Cj0715, Cj1018c, Cj1380, Cj1643, alum
ACE011a	Cj0092, Cj0143c, Cj0420, Cj0772c, alum
15 ACE011b	Cj0715, Cj1018c, Cj1380, Cj1643, alum
ACE017	Cj0092, Cj0143c, Cj0420, Cj0772c, Cj1018c, Cj1380, Cj1643, cel- lulose-binding domain from Clostridium cellulovorans (CBP, Sigma Aldrich C8581), glycine eluate from C.j. strains mentioned in the text.

20

Figure 4. shows the sequence listing of the present application.

Table 1. Occurrence of 8 antigens in 13 randomly selected *Campylobacter jejuni* and one *Campylobacter coli* strain. Whole cell bacterial cell lysate from 14 strains listed was Western blotted and probed with sera against all 8 antigens.

25

List 1 from Danish priority application PA 2003 01726, filed November 21, 2003 and US provisional application 60/524,617, filed November 25, 2003 is incorporated by reference.

30

### **Compositions for use as a medicament**

In a first main aspect, the invention relates to a composition comprising

35

- a polypeptide which comprises a sequence selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,

- an expression vector comprising a sequence encoding said polypeptide,
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector, or
- an antibody capable of binding said polypeptide,

5 for use as a medicament.

In an important embodiment, the composition comprises

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector.

15 Said composition can be used as a vaccine for active immunisation of an individual in need thereof. This is described in the section 'vaccine compositions and methods of vaccination of the invention'.

20 In one preferred embodiment, the composition comprises a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-36 or comprises antigenic fragment or variant of said sequence. In another preferred embodiment, the composition comprises a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:37-51 or comprises antigenic fragment or variant of said sequence.

25 In another important embodiment, the composition comprises an antibody capable of binding a polypeptide selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51.

30 Said composition can e.g. be used in passive immunisation of an individual in need thereof. This is described in the section 'antibodies and methods for raising antibodies of the invention'.

#### **Vaccine compositions and methods of vaccination of the invention**

35 The goal of vaccination or active immunisation is to provide protective immunity by inducing a memory response to an infectious microorganism using an antigenic or

immunogenic composition. Thus, a vaccine is a composition capable of inducing a protective immune response against a microorganism in a human being or animal. Such an immune response can be a cellular response and/or a humoral response, e.g. a specific T cell response or an antibody response.

5

Accordingly, in an important embodiment, the composition is a vaccine composition. I.e. the invention relates to the use of a composition comprising

- a polypeptide which comprises a sequence selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

15

as a vaccine.

The variant herein preferably has at least 95% sequence identity, such as at least 96%, e.g. at least 97%, such as at least 98%, e.g. at least 99% sequence identity to said sequence.

20

In one embodiment of the above composition, the polypeptide comprises SEQ ID NO:1, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:2, or an antigenic fragment or variant thereof.

25

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:3, or an antigenic fragment or variant thereof.

30

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:4, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:5, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:6, or an antigenic fragment or variant thereof.

5 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:7, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:8, or an antigenic fragment or variant thereof.

10 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:9, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:10, or an antigenic fragment or variant thereof.

15 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:11, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:12, or an antigenic fragment or variant thereof.

20 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:13, or an antigenic fragment or variant thereof.

25 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:14, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:15, or an antigenic fragment or variant thereof.

30 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:16, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:17, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:18, or an antigenic fragment or variant thereof.

5 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:19, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:20, or an antigenic fragment or variant thereof.

10 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:21, or an antigenic fragment or variant thereof.

15 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:22, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:23, or an antigenic fragment or variant thereof.

20 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:24, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:25, or an antigenic fragment or variant thereof.

25 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:26, or an antigenic fragment or variant thereof.

30 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:27, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:28, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:29, or an antigenic fragment or variant thereof.

5 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:30, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:31, or an antigenic fragment or variant thereof.

10 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:32, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:33, or an antigenic fragment or variant thereof.

15 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:34, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:35, or an antigenic fragment or variant thereof.

20 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:36, or an antigenic fragment or variant thereof.

25 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:37, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:38, or an antigenic fragment or variant thereof.

30 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:39, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:40, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:41, or an antigenic fragment or variant thereof.

5 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:42, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:43, or an antigenic fragment or variant thereof. In one preferred embodiment,

10  $X_1$  of SEQ ID NO:43 is V and  $X_2$  is A and  $X_3$  is T. In another preferred embodiment,  $X_1$  of SEQ ID NO:43 is A and  $X_2$  is T and  $X_3$  is A.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:44, or an antigenic fragment or variant thereof.

15

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:45, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ

20 ID NO:46, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:47, or an antigenic fragment or variant thereof.

25 In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:48, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:49, or an antigenic fragment or variant thereof.

30

In another embodiment of the above composition, the polypeptide comprises SEQ ID NO:50, or an antigenic fragment or variant thereof.

In another embodiment of the above composition, the polypeptide comprises SEQ

35 ID NO:51, or an antigenic fragment or variant thereof.

In some embodiments of the composition, the polypeptide consists of a sequence selected from the group of SEQ ID NO:1-51. In other embodiments, the polypeptide comprises a sequence selected from the group of SEQ ID NO:1-51 or an antigenic 5 fragment or variant of said sequence, as well as a tag, such as a his-tag, i.e. a polyhistidine, tag.

The composition may only comprise one polypeptide selected from the group of SEQ ID NO:1-51 or a fragment or variant thereof. However, in other embodiments, 10 the composition comprises more than one polypeptide of the group of SEQ ID NO:1-51 and/or more than one fragment of a polypeptide selected from the group of SEQ ID NO:1-51. Thus, the composition according to the invention may comprise more than one, such as 2, for example 3, such as 4, for example 5, such as 6, for example 15 7, such as 8, for example 9, such as 10, such as a number of polypeptides and/or fragments in the range of from 5 to 10, or more than 10, such as for example in the range of from 10 to 20, different polypeptides selected from the group of SEQ ID NO:1-51 or antigenic fragments or variants thereof.

Similarly, the composition may only comprise one polynucleotide, one expression vector or one recombinant virus or recombinant cell of the invention. However, in other embodiments, the composition comprises more than one polynucleotide, one expression vector or one recombinant virus or recombinant cell of the invention. Thus, the composition according to the invention may comprise more than one, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10, or more than 10, such as for example in the 20 25 range of from 10 to 20, different polynucleotides, expression vectors or recombinant viruses or recombinant cells of the invention as described herein.

Furthermore, in some embodiments, a recombinant cell of the invention may express more than one polypeptide of the group of SEQ ID NO:1-51 and/or more than one antigenic fragment or variant of a polypeptide selected from the 30 group of SEQ ID NO:1-51. Thus, the composition according to the invention may comprise a recombinant cell comprising more than one, such as 2, for example 3, such as 4, for example 5, such as 6, for example 7, such as 8, for example 9, such as 10, such as a number of polypeptides and/or antigenic fragments or variants in the range of from 5 to 10, or more than 10, such as for example in the range of from 35 10 to 20, different polypeptides selected from the group of SEQ ID NO:1-51 or anti-

genic fragments or variants thereof. In another embodiment, the composition for use in the invention comprises multiple of the recombinant viruses or recombinant cells described herein.

5      Vaccines comprising polypeptides

In a preferred embodiment, the invention relates to a composition comprising a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, or an antigenic fragment or variant of said sequence, for use as a vaccine. Preferred fragments and variants are those described in the sections herein that relate to fragments and variants.

10     Accordingly, in this embodiment, the antigenicity or immunogenicity is provided by direct administration of a polypeptide normally located on the surface of a *Campylobacter jejuni* cell. In one particular embodiment, the polypeptides are selected so that the vaccine composition comprises multiple polypeptides capable of associating with different MHC molecules, such as different MHC class I molecules. Preferably, the composition for use as a vaccine comprises polypeptides and/or fragments capable of associating with the most frequently occurring MHC class I molecules. In one particular embodiment of the invention, the composition comprises one or more 15     polypeptides and/or fragments capable of associating to an MHC class I molecule and one or more polypeptides and/or fragments capable of associating with an MHC class II molecule. Hence, the vaccine composition is in some embodiments capable of raising a specific cytotoxic T-cells response and/or a specific helper T-cell response. Association to MHC molecules can e.g. be determined as described by 20     Andersen et al. (1999) *Tissue Antigens* 54:185; or by Tan et al. (1997) *J. Immunol. Methods* 209:25.

25     Adjuvants and immunogenic carriers

30     Preferably, the composition for use as vaccine, i.e. the vaccine composition, of the present invention comprises a pharmaceutically-acceptable carrier as described herein in the section 'Compositions for use in the invention'.

35     The composition can further comprise an adjuvant. Adjuvants are substances whose admixture into the vaccine composition increases or otherwise modifies the immune response to a polypeptide or other antigen. Adjuvants could for example be any of: AlK(SO<sub>4</sub>)<sub>2</sub>, AlNa(SO<sub>4</sub>)<sub>2</sub>, AlNH<sub>4</sub> (SO<sub>4</sub>), silica, alum, Al(OH)<sub>3</sub>, Ca<sub>3</sub>

(PO<sub>4</sub>)<sub>2</sub>, kaolin, carbon, aluminium hydroxide, aluminium phosphate, muramyl dipeptides, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-DMP), N-acetyl-nornuramyl-L-alanyl-D-iso-glutamine (CGP 11687, also referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'2'-dipalmitoyl-sn-glycero-3-hydrophosphoryloxy)-ethylamine (CGP 19835A, also referred to as MTP-PE), RIBI (MPL+TDM+CWS) in a 2% squalene/Tween-80. RTM. emulsion, lipopolysaccharides and derivatives, including lipid A, Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvants, Merck Adjuvant 65, polynucleotides (for example, poly IC and poly AU acids), wax D from *Mycobacterium*, tuberculosis, substances found in *Corynebacterium parvum*, *Bordetella pertussis*, and members of the genus *Brucella*, liposomes or other lipid emulsions, Titermax, ISCOMS, Quil A, ALUN (see US 58767 and 5,554,372), Lipid A derivatives, cholera toxin derivatives, HSP derivatives, LPS derivatives, synthetic peptide matrixes or GMDP, Interleukin 1, Interleukin 2, Montanide ISA-51 and QS-21. Preferred adjuvants to be used with the invention include Montanide ISA-51 and QS-21. Montanide ISA-51 (Seppic, Inc.) is a mineral oil-based adjuvant analogous to incomplete Freund's adjuvant, which is normally administered as an emulsion. QS-21 (Antigenics; Aquila Biopharmaceuticals, Framingham, MA) is a highly purified, water-soluble saponin that handles as an aqueous solution.

Desirable functionalities of adjuvants capable of being used in accordance with the present invention are listed in the below table.

Table 1 Modes of adjuvant action

Action	Adjuvant type	Benefit
1. Immunomodulation	Generally small molecules or proteins which modify the cytokine network	Upregulation of immune response. Selection of Th1 or Th2
2. Presentation	Generally amphipathic molecules or complexes which interact with immunogen in its native conformation	Increased neutralizing antibody response. Greater duration of response
3. CTL Induction	<ul style="list-style-type: none"> <li>Particles which can bind or enclose immunogen and which can fuse with or disrupt cell membranes</li> <li>w/o emulsions for direct attachment of peptide to cell surface MHC-1</li> </ul>	Cytosolic processing of protein yielding correct class 1 restricted peptides Simple process if promiscuous peptide(s) known
4. Targeting	<ul style="list-style-type: none"> <li>Particulate adjuvants which bind immunogen. Adjuvants which saturate Kupffer cells</li> <li>Carbohydrate adjuvants which target lectin receptors on macrophages and DCs</li> </ul>	Efficient use of adjuvant and immunogen
5. Depot generation	<ul style="list-style-type: none"> <li>w/o emulsion for short term</li> <li>Microspheres or nanospheres for long term</li> </ul>	As above. May also determine type of response if targeting selective Efficiency Potential for single-dose vaccine

Source: John C. Cox and Alan R. Coulter Vaccine 1997 Feb;15(3):248-56

A vaccine composition according to the present invention may comprise more than one different adjuvant. It is also contemplated that the *Campylobacter* polypeptide of

the invention, or one or more fragments thereof, and the adjuvant can be administered separately in any appropriate sequence.

Frequently, the adjuvant of choice is Freund's complete or incomplete adjuvant, or killed *B. pertussis* organisms, used e.g. in combination with alum precipitated antigen. A general discussion of adjuvants is provided in Goding, *Monoclonal Antibodies: Principles & Practice* (2nd edition, 1986) at pages 61-63. Goding notes, however, that when the antigen of interest is of low molecular weight, or is poorly immunogenic, coupling to an immunogenic carrier is recommended (see below). Various saponin extracts and cytokines have also been suggested to be useful as adjuvants in immunogenic compositions. Recently, it has been proposed to use granulocyte-macrophage colony stimulating factor (GM-CSF), a well known cytokine, as an adjuvant (WO 97/28816).

In addition, a vaccine composition of the invention can comprise an immunogenic carrier such as a scaffold structure, for example a protein or a polysaccharide, to which the *Campylobacter* polypeptide or the fragment thereof is capable of being associated. A *Campylobacter* polypeptide, or the antigenic fragment or variant thereof, present in the vaccine composition can be associated with an immunogenic carrier such as e.g. a protein. The binding or association of the polypeptide to a carrier protein may be covalent or non-covalent. An immunogenic carrier protein may be present independently of an adjuvant. The function of a carrier protein can for example be to increase the molecular weight of in particular fragments in order to increase their activity or immunogenicity, to confer stability, to increase the biological activity, or to increase serum half-life. Furthermore, an immunogenic carrier protein may aid presenting the *Campylobacter* polypeptide or the fragments thereof to T-cells. A carrier protein could be, but is not limited to, keyhole limpet hemocyanin, serum proteins such as transferrin, bovine serum albumin, human serum albumin, thyroglobulin or ovalbumin, immunoglobulins, or hormones, such as insulin. Tetanus toxoid and/or diphtheria toxoid are also suitable carriers in one embodiment of the invention. Alternatively or additionally, dextrans, for example sepharose may be added. In yet another embodiment, an antigen-presenting cell such as e.g. a dendritic cell capable of presenting the polypeptide or a fragment thereof to a T-cell may be added to obtain the same effect as a carrier protein.

Methods for the preparation of vaccine compositions have e.g. been described in US 5,470,958 and references therein. An effective amount of the polypeptide component of a vaccine composition of the invention, if injected, will typically be in the range of from about 0.1 to about 1000 µg, such as e.g. from about 1 to about 900 5 µg, for example from about 5 to about 500 µg, for a human subject, and generally in the range of from about 0.01 to 10.0 µg/Kg body weight of a subject animal. The above-indicated ranges are merely indicative and should not be interpreted as limiting the present invention.

An effective amount of an antigenic polypeptide of the invention may be an 10 amount capable of eliciting a detectable humoral immune response in the absence of an immunomodulator. For many immunogens, this is in the range of about 5-100 µg for a human subject. The appropriate amount of immunogen to be used is dependent on the immunological response it is desired to elicit. Furthermore, the exact 15 effective amount necessary will vary from subject to subject, depending on the species, age and general condition of the subject, the severity of the condition being treated, the mode of administration, etc. It is therefore not always possible to specify an exact effective amount. However, the appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation or prior knowledge in the art.

20

DNA vaccine compositions and vaccine compositions comprising recombinant viruses or recombinant cells

DNA or RNA vaccines pertain to the introduction of e.g. an antigenic polypeptide determinant into a patient by overexpressing in the cells of the patient, a polynucleotide construct which includes expression control sequences operably linked to a 25 sequence encoding the polypeptide of interest, herein a polypeptide of any of SEQ ID NO:1-51 or an antigenic fragment or variant thereof. As such fragments may not contain a methionine start codon, such a codon is optionally included as part of the expression control sequences. The polynucleotide construct may be a non- 30 replicating and linear polynucleotide, a circular expression vector, or an autonomously replicating plasmid or viral expression vector. The construct may become integrated into the host genome. Any expression vector that can transfect a mammalian cell may be used in the methods of immunising an individual according to the present invention. Methods for constructing expression vectors are well known in the

art (see, e.g., Molecular Cloning: A Laboratory Manual, Sambrook et al., eds., Cold Spring Harbor Laboratory, 2nd Edition, Cold Spring Harbor, N.Y., 1989). Preferred are compositions comprising a plurality of genes expressing multiple polypeptides selected from SEQ ID NO:1-51 and/or multiple antigenic fragments of the invention, 5 thereby permitting simultaneous vaccination against a variety of preselected targets.

Vaccines can also be prepared by incorporating a polynucleotide encoding a specific antigenic polypeptide of interest into a living but harmless vector, such as a virus or a cell, such as an attenuated or reduced-virulence *E. coli* or *Salmonella* cell. The harmless recombinant virus or recombinant cell is injected into the intended recipient. Such a recombinant cell may be dead or alive. If alive, the recombinant organism may replicate in the host while producing and presenting the antigenic polypeptide to the host's immune system. It is contemplated that this type of vaccine may be more effective than the non-replicative type of vaccine. For such a vaccine to be successful, the vector organism must be viable, and either be naturally 10 non-virulent or have an attenuated or reduced-virulence phenotype. 15

Strategies for vaccination using attenuated bacteria and suitable bacterial strains for use therein have been described in e.g. Makino et al. (2001) *Microb. Pathog.* 31:1-8; Gentsch et al. (2002) *Int. J. Med. Microbiol.* 291:577-582; Turner et al. (2001) *Infect. Immun.* 69:4969-4979; WO99/49026; and WO03/022307.

Further examples of vectors that can be applied are vectors comprising e.g., retroviruses, as disclosed in WO 90/07936, WO 91/02805, WO 93/25234, WO 93/25698, and WO 94/03622, adenovirus, as disclosed by Berkner, *Biotechniques* 6:616-627, 1988; Li et al., *Hum. Gene Ther.* 4:403-409, 1993; Vincent et al., *Nat. Genet.* 5:130-134, 1993; and Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 20 Further examples of vectors that can be applied are vectors comprising e.g., retroviruses, as disclosed in WO 90/07936, WO 91/02805, WO 93/25234, WO 93/25698, and WO 94/03622, adenovirus, as disclosed by Berkner, *Biotechniques* 6:616-627, 1988; Li et al., *Hum. Gene Ther.* 4:403-409, 1993; Vincent et al., *Nat. Genet.* 5:130-134, 1993; and Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994), pox virus, as disclosed by U.S. 4,769,330; U.S. Pat. No. 5,017,487; and WO 89/01973, naked DNA as disclosed WO 90/11092, a polynucleotide molecule complexed to a polycationic molecule as disclosed in WO 93/03709, and polynucleotides 25 associated with liposomes as disclosed by Wang et al., *Proc. Natl. Acad. Sci. USA* 84:7851, 1987. In certain embodiments, the DNA may be linked to killed or inactivated adenovirus as disclosed by Curiel et al., *Hum. Gene Ther.* 3:147-154, 1992; Cotton et al., *Proc. Natl. Acad. Sci. USA* 89:6094, 1992. Other suitable compositions 30 include DNA-ligands as disclosed by Wu et al., *J. Biol. Chem.* 264:16985-16987, 1989), and lipid-DNA combinations as disclosed by Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413-7417, 1989). In addition, the efficiency of naked DNA uptake into 35 cells may be increased by coating the DNA onto biodegradable latex beads.

Vaccine vectors preferably comprise a suitable promoter which is operably linked to the polynucleotide sequence encoding the immunogenic polypeptide. Any promoter that can direct a high level of transcription initiation in the target cells may be used in the invention. Non-tissue specific promoters, such as the cytomegalovirus (DeBernardi et al., Proc Natl Acad Sci USA 88:9257-9261 [1991], and references therein), mouse metallothionein I (Hammer et al., J Mol Appl Gen 1:273-288 [1982]), HSV thymidine kinase (McKnight, Cell 31:355-365 [1982]), and SV40 early (Benoist et al., Nature 290:304-310 [1981]) promoters may thus also be used.

10 Methods of vaccination

In a further main aspect, the present invention relates to the use of any one or more of

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

15 20 for the preparation of a medicament for the immunisation of an animal or human being against *Campylobacter jejuni* infections. The immunisation preferably induces a protective immune response.

Similarly, the invention relates to a method for the immunisation of an animal or 25 human being against a *Campylobacter jejuni* infections comprising the step of administering any one or more of

- a polypeptide which comprises any of the sequences of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51; or comprises a fragment or variant of any of said sequences,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

30 35 thereby immunising said animal or human being against *Campylobacter jejuni* infections.

The animal may be any bird or mammal, e.g. a chicken, duck, turkey, cow or pig. Particular target populations of human beings may be individuals from at-risk populations, such as the population of children up to 4 years old, the population of 5 persons in industrialised nations or the population of naive or semi-immune travellers to the developing world.

Modes of administration of the composition according to the invention include, but are not limited to systemic administration, such as intravenous or subcutaneous administration, intradermal administration, intramuscular administration, 10 intranasal administration, oral administration, and generally any form of mucosal administration.

The immunogenic effect according to the present invention can e.g. be measured by assay of antibodies in serum samples e.g. by a RIA. Furthermore, the effect can be 15 determined in vivo, by measuring e.g. an increased T cell responsiveness to T cell dependent antigenic polypeptides, wherein said increased responsiveness is characteristic of an enhancement of a normal immune response to such antigenic polypeptides. An immunostimulating effect may also be measured as an enhanced T cell production of, in particular, IL-2, IL-3, IFN- $\gamma$  and/or GM-CSF. Polypeptides or fragments 20 thereof having a potential for eliciting an enhanced immune response may thus be readily identified by screening for enhanced IL-2, IL-3, IFN- $\gamma$  or GM-CSF production by T cells, as described e.g. in US 07/779,499, incorporated herein by reference. Young et al. (2000) In: *Campylobacter*, 2<sup>nd</sup> ed. Ed. by Nachamkin and Blaser, American Society for Microbiology, pp. 287-301 also describe a series of 25 suitable animal models which can be of use in the evaluation of the efficacy of therapeutic and preventive strategies and compositions. A number of aspects related to vaccination against *Campylobacter*, including potential target populations, animal models and vaccination strategies have been described by Scott and Tribble (2000) In: *Campylobacter*, 2<sup>nd</sup> ed. Ed. by Nachamkin and Blaser, American Society 30 for Microbiology, pp. 303-319).

The herein described polynucleotides and expression vectors can be introduced into target cells in vivo or in vitro by any standard method: e.g., as naked DNA (Donnelly et al., *Annu Rev Immunol* 15:617-648 [1997]), incorporated into IS-COMS, liposomes, or erythrocyte ghosts, or by biolistic transfer, calcium precipitation, 35 or electroporation. Alternatively, one can employ a viral-based vector as a

means for introducing the polynucleotide encoding the polypeptide of interest into the cells of the animal or human being. Preferred viral vectors include those derived from replication-defective hepatitis viruses (e.g., HBV and HCV), retroviruses (see, e.g., WO89/07136; and Rosenberg et al., N Eng J Med 323 (9):570-578 [1990]), 5 adenovirus (see, e.g., Morsey et al., J Cell Biochem, Supp. 17E [1993]), adeno-associated virus (Kotin et al., Proc Natl Acad Sci USA 87:2211-2215 [1990]), replication defective herpes simplex viruses (HSV; Lu et al., Abstract, page 66, Abstracts of the Meeting on Gene Therapy, Sep. 22-26, 1992, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.), canary pox virus, and any modified versions of these 10 vectors. Cells transfected in vitro can be cultured and cloned, if desired, prior to introduction into the patient.

In addition to direct in vivo procedures, ex vivo procedures may be used in which cells are removed from an animal, modified, and placed into the same or another animal. It will be evident that one can utilise any of the compositions noted 15 above for introduction of an antigenic polypeptides or polynucleotides encoding such according to the invention into tissue cells in an ex vivo context. Protocols for viral, physical and chemical methods of uptake are well known in the art. Thus, as an alternative to administration of a polypeptide of the invention or a vector capable of expressing such a polypeptide directly to the patient, one can remove helper T cells 20 from the patient; stimulate those T cells ex vivo using the same antigenic polypeptide or vector; and introduce the stimulated helper T cells into the same patient.

#### **Antibodies and methods for raising antibodies of the invention**

In a further main embodiment, the composition for use as a medicament comprises 25 an antibody capable of binding a polypeptide selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51. Such a medicament can be used for antibody therapy, such as passive immunisation of an individual in need thereof.

30 Accordingly, in a further main aspect, the invention relates to antibodies capable of binding, preferably specifically binding, a polypeptide selected from the group consisting of SEQ ID NO:1-36 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:1 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:2 and/or a fragment and/or a variant thereof, such as 35 the polypeptide of SEQ ID NO:3 and/or a fragment and/or a variant thereof, for ex-



variant thereof. 'Specifically binding' is, in this context, not intended to mean absolute specificity. The antibody may in some embodiments also specifically bind polypeptides, e.g. from other *Campylobacter* species, with a high degree of sequence identity to the polypeptide from *Campylobacter jejuni*, e.g. polypeptides with more than 90%, such as more than 95% or more than 98% sequence identity of the polypeptide from *Campylobacter jejuni*.

In a preferred embodiment, the antibody is capable of binding, preferably specifically binding, a polypeptide selected from the group consisting of SEQ ID NO:1-36, such as the polypeptide of SEQ ID NO:1, for example the polypeptide of SEQ ID NO:2, such as the polypeptide of SEQ ID NO:3, for example the polypeptide of SEQ ID NO:4, such as the polypeptide of SEQ ID NO:5, for example the polypeptide of SEQ ID NO:6, such as the polypeptide of SEQ ID NO:7, for example the polypeptide of SEQ ID NO:8, such as the polypeptide of SEQ ID NO:9, for example the polypeptide of SEQ ID NO:10, such as the polypeptide of SEQ ID NO:11, for example the polypeptide of SEQ ID NO:12, such as the polypeptide of SEQ ID NO:13, for example the polypeptide of SEQ ID NO:14, such as the polypeptide of SEQ ID NO:15, for example the polypeptide of SEQ ID NO:16, such as the polypeptide of SEQ ID NO:17, for example the polypeptide of SEQ ID NO:18, such as the polypeptide of SEQ ID NO:19, for example the polypeptide of SEQ ID NO:20, such as the polypeptide of SEQ ID NO:21, for example the polypeptide of SEQ ID NO:22, such as the polypeptide of SEQ ID NO:23, for example the polypeptide of SEQ ID NO:24, such as the polypeptide of SEQ ID NO:25, for example the polypeptide of SEQ ID NO:26, such as the polypeptide of SEQ ID NO:27, for example the polypeptide of SEQ ID NO:28, such as the polypeptide of SEQ ID NO:29, for example the polypeptide of SEQ ID NO:30, such as the polypeptide of SEQ ID NO:31, for example the polypeptide of SEQ ID NO:32, such as the polypeptide of SEQ ID NO:33, for example the polypeptide of SEQ ID NO:34, such as the polypeptide of SEQ ID NO:35, for example the polypeptide of SEQ ID NO:36.

In preferred embodiments, the antibodies of the invention are furthermore capable of binding an intact *Campylobacter jejuni* cell, i.e. capable of binding a living or a dead *Campylobacter* cell which has maintained its structural integrity, preferably a cell that has maintained the integrity of the outer membrane (i.e. wherein the outer membrane has not been permeabilised). Binding of antibodies to intact cells can e.g. be determined by flow cytometry as described in Rioux et al.(2001) Infect. Im-

mun. 69:5162-5165 or as described in Singh et al. (2003) Infect. Immun. 71:3937-3946.

In another main aspect, the invention relates to an antibody capable of binding, preferably specifically binding, an intact *Campylobacter jejuni* cell and capable of binding, preferably specifically binding, a polypeptide selected from the group consisting of SEQ ID NO:37-51 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:37 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:38 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:39 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:40 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:41 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:42 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:43 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:44 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:45 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:46 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:47 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:48 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:49 and/or a fragment and/or a variant thereof, for example the polypeptide of SEQ ID NO:50 and/or a fragment and/or a variant thereof, such as the polypeptide of SEQ ID NO:51 and/or a fragment and/or a variant thereof.

In a preferred embodiment, the antibody is capable of binding, preferably specifically binding, an intact *Campylobacter jejuni* cell and capable of binding, preferably specifically binding, a polypeptide selected from the group consisting of SEQ ID NO:37-51, such as the polypeptide of SEQ ID NO:37, for example the polypeptide of SEQ ID NO:38, such as the polypeptide of SEQ ID NO:39, for example the polypeptide of SEQ ID NO:40, such as the polypeptide of SEQ ID NO:41, for example the polypeptide of SEQ ID NO:42, such as the polypeptide of SEQ ID NO:43, for example the polypeptide of SEQ ID NO:44, such as the polypeptide of SEQ ID NO:45, for example the polypeptide of SEQ ID NO:46, such as the polypeptide of SEQ ID NO:47, for example the polypeptide of SEQ ID NO:48, such as the polypeptide of SEQ ID

NO:49, for example the polypeptide of SEQ ID NO:50, such as the polypeptide of SEQ ID NO:51.

Preferred antibodies are ones that bind with a dissociation constant or Kd of less than  $5 \times 10^{-6}$ M, such as less than  $10^{-6}$ M, e.g. less than  $5 \times 10^{-7}$ M, such as less than  $10^{-7}$ M, e.g. less than  $5 \times 10^{-8}$ M, such as less than  $10^{-8}$ M, e.g. less than  $5 \times 10^{-9}$ M, such as less than  $10^{-9}$ M, e.g. less than  $5 \times 10^{-10}$ M, such as less than  $10^{-10}$ M, e.g. less than  $5 \times 10^{-11}$ M, such as less than  $10^{-11}$ M, e.g. less than  $5 \times 10^{-12}$ M, such as less than  $10^{-12}$ M, e.g. less than  $5 \times 10^{-13}$ M, such as less than  $10^{-13}$ M, e.g. less than  $5 \times 10^{-14}$ M, such as less than  $10^{-14}$ M, e.g. less than  $5 \times 10^{-15}$ M, or less than  $10^{-15}$ M. Binding constants can be determined using methods well-known in the art, such as ELISA (e.g. as described in Orosz and Ovadi (2002) *J. Immunol. Methods* 270:155-162) or surface plasmon resonance analysis.

Antibodies can be used for passive immunisation of mammals, preferably human beings, more preferably immunocompromised patients. A treatment with antibodies can be done to cure or to prevent *Campylobacter jejuni* infections.

Antibodies of the invention include the following preferred mechanistic groups:

1. Function-inhibiting antibodies that work as an antibacterial (affect the viability of the bacterium). Such antibodies should be effective regardless of the immune status of the patient. Preferably, such antibodies are capable of reducing *Campylobacter jejuni* growth in vitro to less than 50%, such as less than 25%, for example less than 10%, such as less than 5% of a control without antibody added.
2. Opsonising antibodies that are designed to enhance phagocytic killing. Effectiveness of such antibodies may depend on the immune status of the patient, but it is very well possible that they will enhance phagocytic killing even in compromised patients.
3. Antibodies conjugated to a therapeutic moiety such as a toxin or bactericidal agent, e.g. ricin or radioisotopes. Techniques for conjugating a therapeutic moiety to antibodies are well known, see, e.g. Thorpe et al.(1982) *Immunol. Rev.* 62, 119-158. These antibodies should also be effective regardless of the immune status of the patient.

An antibody with or without a therapeutic moiety conjugated to it can be used as a therapeutic that is administered alone or in combination with chemotherapeutics or other therapeutic agents.

5 In one embodiment, the antibodies of the invention are opsonising as well as function-inhibiting. In another embodiment, the antibodies of the invention are opsonising but not function-inhibiting. The latter group of antibodies can e.g. be antibodies directed against a target polypeptide which is not essential for the viability of *Campylobacter*.

10

In a further main aspect, the invention relates to a method for raising antibodies to a polypeptide selected from the group consisting of SEQ ID NO:1-36 in a non-human animal comprising the steps of

15 a. providing

- a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1-36, or comprising an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,

20 - an expression vector comprising a sequence encoding said polypeptide, or

- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

25 b. introducing a composition comprising said polypeptide, polynucleotide, vector, recombinant virus or recombinant cell into said animal,

c. raising antibodies in said animal, and

d. isolating and optionally purifying the antibodies.

30 In another main aspect, the invention relates to a method for raising antibodies to a polypeptide selected from the group consisting of SEQ ID NO:37-51 in an non-human animal, wherein the antibodies are capable of binding an intact *Campylobacter jejuni* cell, the method comprising the steps of

a. providing

- a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:37-51, or comprising antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- 5 - an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

b. introducing a composition comprising said polypeptide, polynucleotide, vector, recombinant virus or recombinant cell into said animal,

10 c. raising antibodies in said animal,

d. isolating and optionally purifying the antibodies, and

e. selecting antibodies capable of binding an intact *Campylobacter jejuni* cell.

15 The above methods are preferably done in a transgenic animal which is capable of producing human antibodies. In a further preferred embodiment, the above methods are non-therapeutic.

#### Monoclonal/polyclonal antibodies

20 Antibodies of the invention may be polyclonal antibodies or monoclonal antibodies or mixtures of monoclonal antibodies. In a preferred embodiment, the antibody is a monoclonal antibody or a fragment thereof. Monoclonal antibodies (Mab's) are antibodies wherein every antibody molecule is similar and thus recognises the same epitope. The antibody may be any kind of antibody, however, it is preferably an IgG or IgA antibody.

25

Monoclonal antibodies are in general produced by a hybridoma cell line. Methods of making monoclonal antibodies and antibody-synthesising hybridoma cells are well known to those skilled in the art. Antibody-producing hybridomas may for example be prepared by fusion of an antibody-producing B lymphocyte with an 30 immortalised cell line. A monoclonal antibody can be produced by the following steps. An animal is immunised with an antigen such as a full-length polypeptide or a fragment thereof. The immunisation is typically accomplished by administering the antigen to an immunologically competent mammal in an immunologically effective amount, i.e., an amount sufficient to produce an immune response. Preferably, the 35 mammal is a rodent such as a rabbit, rat or mouse. The mammal is then maintained

on a booster schedule for a time period sufficient for the mammal to generate high affinity antibody molecules. A suspension of antibody-producing cells is removed from each immunised mammal secreting the desired antibody. After a sufficient time to generate high affinity antibodies, the animal (e.g. mouse) is sacrificed and anti-  
5 body-producing lymphocytes are obtained from one or more of the lymph nodes, spleens and peripheral blood. Spleen cells are preferred, and can be mechanically separated into individual cells in a physiological medium using methods well known to one of skill in the art. The antibody-producing cells are immortalised by fusion to cells of a mouse myeloma line. Mouse lymphocytes give a high percentage of stable  
10 fusions with mouse homologous myelomas, however, rat, rabbit and frog somatic cells can also be used. Spleen cells of the desired antibody-producing animals are immortalised by fusing with myeloma cells, generally in the presence of a fusing agent such as polyethylene glycol. Any of a number of myeloma cell lines suitable as a fusion partner can be, for example, the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or  
15 Sp2/O-Ag14 myeloma lines, available from the American Type Culture Collection (ATCC), Rockville, Md.

Monoclonal antibodies can also be generated by other methods well known to those skilled in the art of recombinant DNA technology. An alternative method, referred to as the "combinatorial antibody display" method, has been developed to  
20 identify and isolate antibody fragments having a particular specificity, and can be utilised to produce monoclonal antibodies.

A polyclonal antibody is a mixture of antibody molecules recognising a specific given antigen, hence polyclonal antibodies may recognise different epitopes within e.g. a polypeptide. In general polyclonal antibodies are purified from serum of  
25 a mammal, which previously has been immunised with the antigen. Polyclonal antibodies may for example be prepared by any of the methods described in *Antibodies: A Laboratory Manual*, By Ed Harlow and David Lane, *Cold Spring Harbor Laboratory Press*, 1988. Polyclonal antibodies may be derived from any suitable mammalian species, for example from mice, rats, rabbits, donkeys, goats, and sheep.

30

#### Specificity

The antibodies of the invention may be monospecific towards any of the polypeptides of SEQ ID NO:1-51. In another embodiment, the antibody is bispecific or multispecific having at least one portion being specific towards any of the polypeptides  
35 of SEQ ID NO:1-51.

Monospecific antibodies may be monovalent, i.e. having only one binding domain. For a monovalent antibody, the immunoglobulin constant domain amino-acid sequences preferably comprise the structural portions of an antibody molecule known in the art as CH1, CH2, CH3 and CH4. Preferred are those which are known 5 in the art as C<sub>L</sub>. Furthermore, insofar as the constant domain can be either a heavy or light chain constant domain (C<sub>H</sub> or C<sub>L</sub>, respectively), a variety of monovalent antibody compositions are contemplated by the present invention. For example, light chain constant domains are capable of disulphide bridging to either another light chain constant domain, or to a heavy chain constant domain. In contrast, a heavy 10 chain constant domain can form two independent disulphide bridges, allowing for the possibility of bridging to both another heavy chain and to a light chain, or to form polymers of heavy chains. Thus, in another embodiment, the invention contemplates a composition comprising a monovalent polypeptide wherein the constant chain domain C has a cysteine residue capable of forming at least one disulphide bridge, 15 and where the composition comprises at least two monovalent polypeptides covalently linked by said disulphide bridge.

In another embodiment of the invention the antibody is a multivalent antibody having at least two binding domains. The binding domains may have specificity for the same ligand or for different ligands.

20

#### Multispecificity, including bispecificity

In a preferred embodiment the invention relates to multispecific antibodies, which have affinity for and are capable of specifically binding at least two different entities.

25

In one embodiment, the multispecific antibody is a bispecific antibody, which carries at least two different binding domains, at least one of which is of antibody origin. A bispecific molecule of the invention can also be a single chain bispecific molecule. Multispecific molecules can also be single-chain molecules or may comprise at least two single-chain molecules. The multispecific, including bispecific antibodies, may be produced by any suitable manner known to the person skilled in 30 the art. A number of approaches have been developed such as the ones described in WO 94/09131; WO 94/13804; WO 94/13806 or U.S. Pat. Nos. 5,260,203; 5,455,030; 4,881,175; 5,132,405; 5,091,513; 5,476,786; 5,013,653; 5,258,498; and 5,482,858.

35

Using a bispecific or multispecific antibody according to the invention the invention offers several advantages as compared to monospecific/monovalent antibodies. A

bispecific/multispecific antibody has a first binding domain capable of specifically recognising and binding any of the *Campylobacter jejuni* polypeptides of SEQ ID NO:1-51, whereas the other binding domain(s) may be used for other purposes. In one embodiment, at least one other binding domain is used for binding to a *Campylobacter jejuni* polypeptide, such as binding to another epitope on the same *Campylobacter jejuni* polypeptide as the first binding domain. Thereby specificity for *Campylobacter jejuni* may be increased as well as increase of avidity of the antibody. In another embodiment the at least one other binding domain may be used for specifically binding a mammalian cell, such as a human cell. It is preferred that the at least 5 other binding domain is capable of binding an immunoactive cell, such as a leucocyte, a macrophage, a lymphocyte, a basophilic cell, and/or an eosinophilic cell, in order to increase the effect of the antibody in a therapeutic method. This may be accomplished by establishing that the at least one other binding domain is capable 10 of specifically binding a mammalian protein, such as a human protein, such as a protein selected from any of the cluster differentiation proteins (CD), in particular 15 CD64 and/or CD89.

#### Humanised antibodies

It is not always desirable to use non-human antibodies for human therapy, since the 20 non-human "foreign" epitopes may elicit an immune response in the individual to be treated. To eliminate or minimise the problems associated with non-human antibodies, it is desirable to engineer chimeric antibody derivatives, i.e., "humanised" antibody molecules that combine the non-human Fab variable region binding determinants with a human constant region (Fc). Such antibodies are characterised by 25 equivalent antigen specificity and affinity of the monoclonal and polyclonal antibodies described above, and are less immunogenic when administered to humans, and therefore more likely to be tolerated by the individual to be treated.

Accordingly, in one embodiment the antibody of the invention is a humanised antibody. Humanised antibodies are in general chimeric antibodies comprising 30 regions derived from a human antibody and regions derived from a non-human antibody, such as a rodent antibody. Humanisation (also called Reshaping or CDR-grafting) is a well-established technique for reducing the immunogenicity of monoclonal antibodies (mAbs) from xenogeneic sources (commonly rodent), increasing the homology to a human immunoglobulin, and for improving their activation of the 35 human immune system. Thus, humanised antibodies are typically human antibodies

in which some CDR residues and possibly some framework residues are substituted by residues from analogous sites in rodent antibodies.

It is important that humanised antibodies retain high affinity for the antigen and other favourable biological properties. To achieve this goal, according to a preferred method, humanised antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanised products using three-dimensional models of the parental and humanised sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of certain residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is maximised, although it is the CDR residues that directly and most substantially influence antigen binding.

One method for humanising MAbs relates to production of chimeric antibodies in which an antigen binding site comprising the complete variable domains of one antibody is fused to constant domains derived from a second antibody, preferably a human antibody. Methods for carrying out such chimerisation procedures are for example described in EP-A-0 120 694 (Celltech Limited), EP-A-0 125 023 (Genentech Inc.), EP-A-0 171 496 (Res. Dev. Corp. Japan), EP-A-0173494 (Stanford University) and EP-A-0 194 276 (Celltech Limited).

The humanised antibody of the present invention may be made by any method capable of replacing at least a portion of a CDR of a human antibody with a CDR derived from a non-human antibody. Winter describes a method which may be used to prepare the humanised antibodies of the present invention (UK Patent Application GB 2188638A), the contents of which are incorporated by reference.

As an example, the humanised antibodies of the present invention may be produced by the following process:

(a) constructing, by conventional techniques, an expression vector containing an operon with a DNA sequence encoding an antibody heavy chain in which the CDRs and such minimal portions of the variable domain framework region that are required to retain antibody binding specificity are derived from a non-human

immunoglobulin, and the remaining parts of the antibody chain are derived from a human immunoglobulin;

5 (b) constructing, by conventional techniques, an expression vector containing an operon with a DNA sequence encoding a complementary antibody light chain in which the CDRs and such minimal portions of the variable domain framework region that are required to retain donor antibody binding specificity are derived from a non-human immunoglobulin, and the remaining parts of the antibody chain are derived from a human immunoglobulin;

10 (c) transfecting the expression vectors into a host cell by conventional techniques; and

(d) culturing the transfected cell by conventional techniques to produce the humanised antibody.

15 The host cell may be co-transfected with the two vectors of the invention, the first vector containing an operon encoding a light chain derived polypeptide and the second vector containing an operon encoding a heavy chain derived polypeptide. The two vectors contain different selectable markers, but otherwise, apart from the antibody heavy and light chain coding sequences, are preferably identical, to ensure, as far as possible, equal expression of the heavy and light chain polypeptides. Alternatively, a single vector may be used, the vector including the sequences encoding both the light and the heavy chain polypeptides. The coding sequences for the light and heavy chains may comprise cDNA or genomic DNA or both.

20

25 The host cell used to express the altered antibody of the invention may be either a bacterial cell such as *Escherichia coli*, or a eukaryotic cell. In particular a mammalian cell of a well defined type for this purpose, such as a myeloma cell or a Chinese hamster ovary cell may be used.

30 The general methods by which the vectors of the invention may be constructed, transfection methods required to produce the host cell of the invention and culture methods required to produce the antibody of the invention from such host cells are all conventional techniques. Likewise, once produced, the humanised antibodies of the invention may be purified according to standard procedures.

Human antibodies

In a more preferred embodiment the invention relates to an antibody, wherein the binding domain is carried by a human antibody, i.e. wherein the antibodies have a greater degree of human peptide sequences than do humanised antibodies.

Human mAb antibodies directed against human proteins can be generated 5 using transgenic mice carrying the human immune system rather than the mouse system. Splenocytes from these transgenic mice immunised with the antigen of interest are used to produce hybridomas that secrete human mAbs with specific affinities for epitopes from a human protein (see, e.g., Wood et al. International Application WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. 10 International Application WO 92/03918; Kay et al. International Application 92/03917; Lonberg, N. et al. 1994 Nature 368:856-859; Green, L. L. et al. 1994 Nature Genet. 7:13-21; Morrison, S. L. et al. 1994 Proc. Natl. Acad. Sci. USA 81:6851-6855; Bruggeman et al. 1993 Year Immunol 7:33-40; Tuailon et al. 1993 PNAS 90:3720-3724; Bruggeman et al. 1991 Eur J Immunol 21:1323-1326). Such trans- 15 genic mice are available from Abgenix, Inc., Fremont, Calif., and Medarex, Inc., An- nandale, N.J. It has been described that the homozygous deletion of the antibody heavy-chain joining region (IH) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the 20 production of human antibodies upon antigen challenge. See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA 90:2551 (1993); Jakobovits et al., Nature 362:255-258 (1993); Bruggemann et al., Year in Immunol. 7:33 (1993); and Duchosal et al. Na- ture 355:258 (1992). Human antibodies can also be derived from phage-display li- 25 braries (Hoogenboom et al., J. Mol. Biol. 227: 381 (1992); Marks et al., J. Mol. Biol. 222:581-597 (1991); Vaughan, et al., Nature Biotech 14:309 (1996)).

Suitable methods for producing human monoclonal antibodies have fur- 30 thermore been described in WO 03/017935, WO 02/100348, US 2003 091561, and US 2003 194403.

30 Binding fragments of antibodies

In one embodiment of the invention, the antibody is a fragment of an antibody, preferably an antigen binding fragment or a variable region. Examples of antibody fragments useful with the present invention include Fab, Fab', F(ab')<sub>2</sub> and Fv fragments. Papain digestion of antibodies produces two identical antigen binding fragments, 35 called the Fab fragment, each with a single antigen binding site, and a residual "Fc"

fragment, so-called for its ability to crystallise readily. Pepsin treatment yields an  $F(ab')_2$  fragment that has two antigen binding fragments which are capable of cross-linking antigen, and a residual other fragment (which is termed pFc'). Additional fragments can include diabodies, linear antibodies, single-chain antibody molecules, 5 and multispecific antibodies formed from antibody fragments.

The antibody fragments Fab, Fv and scFv differ from whole antibodies in that the antibody fragments carry only a single antigen-binding site. Recombinant fragments with two binding sites have been made in several ways, for example, by chemical cross-linking of cysteine residues introduced at the C-terminus of the VH of 10 an Fv (Cumber et al., 1992), or at the C-terminus of the VL of an scFv (Pack and Pluckthun, 1992), or through the hinge cysteine residues of Fab's (Carter et al., 1992).

Preferred antibody fragments retain some or essentially all of the ability of 15 an antibody to selectively binding with its antigen. Some preferred fragments are defined as follows:

- (1) Fab is the fragment that contains a monovalent antigen-binding fragment of an antibody molecule. A Fab fragment can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain.
- 20 (2) Fab' is the fragment of an antibody molecule and can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain. Two Fab' fragments are obtained per antibody molecule. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxyl terminus of the heavy chain CH1 domain including one or 25 more cysteines from the antibody hinge region.
- (3) ( $Fab')_2$  is the fragment of an antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction.  $F(ab')_2$  is a dimer of two Fab' fragments held together by two disulfide bonds.
- 30 (4) Fv is the minimum antibody fragment that contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in a tight, non-covalent association ( $V_H - V_L$  dimer). It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the  $V_H - V_L$  dimer. Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single 35 variable domain (or half of an Fv comprising only three CDRs specific for an an-

tigen) has the ability to recognise and bind antigen, although at a lower affinity than the entire binding site.

5 In one embodiment of the present invention the antibody is a single-chain antibody, defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule. Such single-chain antibodies are also referred to as "single-chain Fv" or "sFv" antibody fragments. Generally, the Fv polypeptide further comprises a polypeptide linker between the  $V_H$  and  $V_L$  domains  
10 that enables the sFv to form the desired structure for antigen binding.

The antibody fragments according to the invention may be produced in any suitable manner known to the person skilled in the art. Several microbial expression systems have already been developed for producing active antibody fragments, e.g. the production of Fab in various hosts, such as *E. coli* or yeast has been described.  
15 The fragments can be produced as Fab's or as Fv's, but additionally it has been shown that a  $V_H$  and a  $V_L$  can be genetically linked in either order by a flexible polypeptide linker, which combination is known as an scFv.

### **Compositions for use in the invention**

20 In a preferred embodiment of the composition for use as a medicament, said composition comprises, in addition to the active component, a pharmaceutically-acceptable carrier.

25 As used herein, the term "pharmaceutically acceptable" used in connection with compositions or carriers represents that the materials are capable of being administered to or upon a human or animal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

30 The preparation of a composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Often such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspension, in liquid prior to use can also be prepared. The preparation can also be emulsified. The active ingredient can be mixed with carriers which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the methods  
35

described herein. Suitable carriers are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of 5 the active ingredient.

The compositions of the present invention can include pharmaceutically-acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed 10 with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine 15 and the like.

Pharmaceutically-acceptable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered 20 saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, organic esters such 25 as ethyl oleate, and water-oil emulsions.

A composition containing a polypeptide or antibody of the present invention preferably contains an amount of at least 0.1 weight percent of polypeptide or antibody per weight of total pharmaceutical composition. A weight percent is a ratio by weight of polypeptide or antibody to total composition. Thus, for example, 0.1 weight 30 percent is 0.1 grams of polypeptide or antibody per 100 grams of total composition.

The composition may also be a kit-in-part further including an antibiotic agent, such as antibiotics selected from  $\beta$ -lactams, cephalosporins, penicillins, aminoglycosides, macrolide antibiotics (erythromycin, clarithromycin, or azithromycin) and fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, gatifloxacin, or moxifloxacin) and/or 35

including an immunostimulating agent, such as cytokines, interferons, growth factors, for example GCSF or GM-CSF. The kit-in-part may be used for simultaneous, sequential or separate administration.

5 The invention furthermore relates to pharmaceutical compositions useful for practising the methods described herein. Thus, the invention relates to a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and

- an isolated polypeptide which comprises any of the sequences of SEQ ID NO:1-36, or comprises a fragment or variant of any of said sequences,

10 - an isolated polynucleotide comprising a sequence encoding said polypeptide,

- an expression vector comprising a sequence encoding said polypeptide,  
or

- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector.

15

Furthermore, the invention relates to a pharmaceutical composition comprising an antibody of the invention as defined herein and a pharmaceutically-acceptable carrier.

20 **Polypeptides of the invention**

Fragments of the invention

In a further aspect, the invention relates to a fragment, preferably an antigenic fragment, of a polypeptide set forth in any of SEQ ID NO:1-51, such as a fragment of any of SEQ ID NO:1-36 or a fragment of any of SEQ ID NO:37-51. The length of 25 such fragments may vary from 2 consecutive amino-acid residues of a polypeptide to the full-length polypeptide minus one amino-acid residue. Preferably, fragments are less than 100 consecutive amino acids, such as less than 70 or 50 consecutive amino acids, e.g. less than consecutive 40 amino acids, such as less than 30 consecutive amino acids, e.g. less than 25 consecutive amino acids, such as less than 30 consecutive 30 amino acids in length. Thus, for example fragments can be 2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19 or 20 consecutive amino acids in length. In further preferred embodiments, a fragment comprises 6 or more, such as 7 or more, e.g. 8 or more, such as 9 or more, e.g. 10 or more consecutive amino acids of the corresponding full-length sequence. Preferred ranges include fragments 35 of between 5 and 50 consecutive amino acids in length, such as between 5 and 25

consecutive amino acids in length, e.g. between 5 and 20 consecutive amino acids in length. Expressed in another way, a fragment consists of a part of an amino-acid sequence which is less than 100% in length as compared to the full-length polypeptide. Preferably, the length of the fragment is less than 99%, such as less than 75%, 5 e.g. less than 50%, such as less than 25%, e.g. less than 20%, such as less than 15%, e.g. less than 10% of the length of the full-length polypeptide. In further preferred embodiments, the fragment consists of a part of an amino-acid sequence which is less than 100%, but more than 1% in length as compared to the full-length polypeptide, such as less than 100% but more than 5%, e.g. less than 100% but 10 more than 10%, such as less than 100% but more than 20%, e.g. less than 100% but more than 25%, such as less than 100% but more than 50% of the length of the full-length polypeptide.

Preferred specific fragments include fragments comprising one or more residues of a fragment selected from the group consisting of SEQ ID NO:52-119, 15 e.g. two or more, such as three or more, e.g. four or more, such as 5 or more residues, e.g. 6 or more consecutive residues of a fragment selected from the group consisting of SEQ ID NO:52-119. Even more preferred specific fragments include fragments consisting of or essentially consisting of a sequence selected from the group consisting of SEQ ID NO:52-119.

20 Other preferred fragment include fragments from List 1 from Danish priority application PA 2003 01726, filed November 21, 2003 and US provisional application 60/524,617, filed November 25, 2003, incorporated herein by reference.

25 Preferably, fragments of the invention are surface-exposed in an intact *Campylobacter jejuni* cell or other cell when expressed recombinantly therein. Surface-exposure can be e.g. be determined using a monoclonal antibody specific for said fragment, e.g. as described in Singh et al. (2003) *Infect. Immun.* 71:3973-3946. Also preferred are fragments which are capable of inducing antibodies that can specifically bind an intact *Campylobacter jejuni* cell. This can be determined by generating monoclonal 30 antibodies using said fragment and subsequent characterisation of the binding of individual antibodies to intact cells, e.g. as described in Singh et al. (2003) *Infect. Immun.* 71:3973-3946.

35 The full-length polypeptides of SEQ ID NO:1-51 as well as the fragments of the invention can be produced recombinantly by conventional techniques known in the

art. Suitable host cells can be mammalian cells, e.g. CHO, COS or HEK293 cells. Alternatively, insect cells, bacterial cells or fungal cells can be used. Methods for heterologous expression of polynucleotide sequences in the cell types listed above and subsequent purification of the produced polypeptides, e.g. using a tag sequence 5 such as a histidine tag, which may be removed after purification, are well-known to those skilled in the art. Alternatively, fragments of the invention can be produced synthetically.

Variants of the invention

10 In a further main aspect, the invention relates to the use of variants of any of the polypeptides set forth in SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51 or variants of fragments of any of the polypeptides set forth in SEQ ID NO:1-51, in a composition for use as a medicament.

15 When used herein, phrases such as 'a polypeptide having at least 95% sequence identity to SEQ ID NO:X' are used interchangeably with, and are intended to be directed to the same subject-matter as, phrases such as 'the polypeptide of SEQ ID NO:X and variants thereof, wherein the variant has at least 95% sequence identity to said sequence.'

20 Variants preferably have at least 75% sequence identity, for example at least 80% sequence identity, such as at least 85% sequence identity, for example at least 90% sequence identity, such as at least 91% sequence identity, such as at least 92% sequence identity, for example at least 93% sequence identity, such as at least 94% sequence identity, for example at least 95% sequence identity, such as at least 96% 25 sequence identity, for example at least 97% sequence identity, such as at least 98% sequence identity, for example 99% sequence identity with the given polypeptide or fragment. Sequence identity is determined with any of the algorithms GAP, BESTFIT, or FASTA in the Wisconsin Genetics Software Package Release 7.0, using default gap weights.

30 Preferred variants of a given polypeptide or fragment are variants in which all amino-acid substitutions between the variant and the given reference polypeptide or fragment are conservative substitutions. Conservative amino-acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group 35 of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and

isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine, a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Preferred conservative amino-acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

Variants of a polypeptide or of a fragment thereof also include forms of the polypeptide or fragment wherein one or more amino acids have been deleted or inserted. Preferably, less than 5, such as less than 4, e.g. less than 3, such as less than 2, e.g. only one amino acid has been inserted or deleted. 'Variants' of a polypeptide or of a fragment thereof also include forms of these polypeptides or fragments modified by post-translational modifications of the amino-acid sequence.

15

### **Polynucleotides and expression vectors of the invention**

In a further aspect, the invention relates to polynucleotides, preferably isolated and/or recombinant polynucleotides, comprising a sequence encoding an antigenic fragment or variant of a sequence selected from the group consisting of SEQ ID NO:1-51, such as a sequence encoding an antigenic fragment or variant of a sequence selected from the group consisting of SEQ ID NO:1-36 or a sequence encoding a antigenic fragment or variant of a sequence selected from the group consisting of SEQ ID NO: 37-51.

Furthermore, the invention relates to expression vectors comprising a sequence encoding a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, or comprises a fragment or variant of any of said sequences. Preferred expression vectors as ones suitable for DNA vaccination. Other preferred expression vectors are ones in which a polynucleotide of the invention is under the control of a promoter that directs expression of the sequence in *Escherichia coli* or *Salmonella*. The latter expression vectors are useful in the production of a recombinant virus or recombinant cell of the invention as described herein.

The polynucleotides and expression vectors of the invention can be prepared by standard recombinant DNA techniques well-known to the person skilled in the art.

**Recombinant cells of the invention**

In a further main aspect, the invention relates to a recombinant cell transformed or transfected with a polynucleotide comprising a sequence encoding a polypeptide, 5 said polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1-36, or comprising an antigenic fragment or variant of said sequence. Preferably, said recombinant cell is an *Escherichia coli* or *Salmonella* cell, more preferably an attenuated or reduced-virulence *Escherichia* or *Salmonella* cell.

In a further aspect, the invention relates to a recombinant attenuated or 10 reduced-virulence microbial cell, preferably an *Escherichia coli* or a *Salmonella* cell transformed or transfected with a polynucleotide comprising a sequence encoding a polypeptide, said polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:37-51, or comprising an antigenic fragment or variant of said sequence.

15 Suitable bacterial strains for use herein have been described in e.g. Makino et al. (2001) *Microb. Pathog.* 31:1-8; Gentschev et al. (2002) *Int. J. Med. Microbiol.* 291:577-582; Turner et al. (2001) *Infect. Immun.* 69:4969-4979; WO99/49026; and WO03/022307 and references therein. Examples of suitable *Salmonella* strains are CVD908-T7pol (Santiago-Machuca et al. (2002) *Plasmid* 47:108-119), ATCC 39183, 20 ATCC 53647 and ATCC 53648. Examples of suitable *E. coli* strains are YT106 and E1392/75-2A.

**Methods and uses of the invention**

The compositions and other products defined above can be used to treat or prevent 25 *Campylobacter jejuni* infections, and/or disease resulting from such infections, in animals or human beings in need thereof. Preferably, the animal is a chicken, duck, turkey, cow or pig. Preferred human populations are at-risk populations, such as the population of children up to 4 years old, the population of persons in industrialised nations or the population of naive or semi-immune travellers to the developing world.

30 Treatment and prevention herein include all types of therapeutic treatment and preventive treatment and other treatments to combat *Campylobacter jejuni*, including but not limited to vaccination, prophylaxis, active immunisation, passive immunisation, administration of antibodies, curative treatment, ameliorating treatment. In par-

ticular, passive immunisation using antibodies of the invention is a suitable treatment for immunocompromised individuals.

Thus, in a further aspect, the invention relates to a method for treatment or prevention of *Campylobacter jejuni* infection in an animal or human being comprising the step of administering any one of the following

- a polypeptide which comprises any of the sequences of SEQ ID NO:1-51, such as any of the sequences of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, or comprises a fragment or variant of any of said sequences,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide,
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector, or
- an antibody capable of specifically binding said polypeptide,

thereby treating or preventing a *Campylobacter jejuni* infections in said animal or human being.

Preferably, said administration is done parenterally, intravenously, intramuscularly, subcutaneously, orally or intranasally.

Preferably, said medicament is a medicament suitable for parenteral, intravenous, intramuscular, subcutaneous, oral or intranasal administration.

In a further aspect, the invention relates to a method for the immunisation of an animal or human being against *Campylobacter jejuni* infections comprising the step of administrating

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, such as any of the sequences of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, or comprises an antigenic fragment or variant of any of said sequences,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

Preferably, said administration is done parenterally, intravenously, intramuscularly, subcutaneously, orally or intranasally.

In a further aspect, the invention relates to the use of an antibody of the invention as defined herein for the manufacture of a medicament for the treatment or prevention of *Campylobacter jejuni* infections in an animal or human being. Thus, the invention also relates to a method for the treatment or prevention of *Campylobacter jejuni* infections comprising the step of administering an antibody of the invention as defined herein, and thereby treating or preventing the *Campylobacter jejuni* infection. Preferably, said administration is done parenterally, intravenously, intramuscularly, subcutaneously, orally or intranasally.

#### **Diagnostic methods of the invention**

The combination of being surface-exposed and being present in relatively high copy numbers in cells also makes the 51 polypeptides identified by the inventors highly suitable as targets for detection of *Campylobacter jejuni*, allowing detection of this organism with high sensitivity.

Accordingly, in a further main aspect, the invention relates to a method for detecting *Campylobacter jejuni* or parts thereof in a sample comprising the steps of

- a. contacting said sample with an indicator moiety capable of specifically binding a polypeptide selected from the group consisting of SEQ ID NO:1-36, and
- b. determining whether a signal has been generated by the indicator moiety, thereby detecting whether said sample contains *Campylobacter jejuni* or parts thereof.

Preferably, said indicator moiety is capable of binding, preferably specifically binding, intact *Campylobacter jejuni* cells.

In another aspect, the invention relates to a method for detecting a *Campylobacter jejuni* comprising the steps of

- a. contacting said sample with an indicator moiety capable of specifically binding a polypeptide selected from the group consisting of SEQ ID NO:37-51, wherein the indicator moiety furthermore is capable of binding, preferably specifically binding, intact *Campylobacter jejuni* cells, and

b. determining whether a signal has been generated by the indicator moiety, thereby detecting whether said sample contains *Campylobacter jejuni* or parts thereof.

5 In preferred embodiments of the above diagnostic methods, a washing step is performed between the contacting step and the determination step, in order to improve the specificity of detection.

10 The sample can e.g. be faeces, urine, a tissue, tissue extract, fluid sample or body fluid sample, such as blood, plasma or serum. Another example of a sample is a food sample, such as a meat sample.

15 The above methods can e.g. be used to diagnose *Campylobacter jejuni* infections or campylobacteriosis in an individual. In preferred embodiments of the above methods, said indicator moiety does not pass through the outer-membrane of a *Campylobacter jejuni* cell. A preferred type of said indicator moiety consists of or comprises an antibody, such as an antibody of the invention as defined herein.

20 Those skilled in the art will understand that there are numerous well known clinical diagnostic chemistry procedures in which an indicator moiety can be used to form an binding reaction product whose amount relates to the amount of the ligand, herein *C. jejuni* or parts thereof, in a sample. Thus, while exemplary assay methods are described herein, the invention is not so limited.

25 The present invention also relates to a diagnostic system, preferably in kit form, for assaying for the presence, and preferably also the amount, of *Campylobacter jejuni* in a biological sample. Methods for the preparation of diagnostic kits have e.g. been described in US 5,470,958 and references therein.

30 The diagnostic system includes, in an amount sufficient to perform at least one assay, an indicator moiety according to the present invention, preferably as a separately packaged reagent, and more preferably also instructions for use. Packaged refers to the use of a solid matrix or material such as glass, plastic (e.g., polyethylene, polypropylene or polycarbonate), paper, foil and the like capable of holding within fixed limits an indicator moiety of the present invention. Thus, for example, a 35 package can be a glass vial used to contain milligram quantities of a contemplated

labelled indicator moiety preparation, or it can be a microtiter plate well to which microgram quantities of a contemplated indicator moiety has been operatively affixed, i.e., linked so as to be capable of binding a ligand.

5 "Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.

10 In most embodiments, the diagnostic method and system of the present invention include as a part of the indicator moiety, a label or indicating means capable of signalling the formation of a binding reaction complex containing an indicator moiety complexed with the preselected ligand (i.e. a polypeptide comprising any of the sequences of SEQ ID NO:1-51 and/or a fragment thereof). Such labels are themselves well-known in clinical diagnostic chemistry.

15 The labelling means can be a fluorescent labelling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer. Suitable fluorescent labelling agents are fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-1-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC), lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC). Other examples of suitable fluorescent materials include umbelliferone, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin and the like. A description of immunofluorescence analysis techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis, et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982).

20 Radioactive elements can be useful as labelling agents. An exemplary radiolabeling agent is a radioactive element that produces gamma ray emissions. Elements which themselves emit gamma rays, such as  $^{124}\text{I}$ ,  $^{125}\text{I}$ ,  $^{128}\text{I}$ ,  $^{132}\text{I}$  and  $^{51}\text{Cr}$  represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly preferred is  $^{125}\text{I}$ . Another group of useful labelling means are those elements such as  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{15}\text{O}$  and  $^{13}\text{N}$  which themselves emit positrons, or beta emitters, such as  $^{111}\text{indium}$  or  $^{3}\text{H}$ . Other suitable radioactive materials include  $^{131}\text{I}$  and  $^{35}\text{S}$ .

25 Detection using antibodies can, in other embodiments, be facilitated by coupling the antibody to another detectable substance, such as an enzyme, a pros-

thetic group, a luminescent materials, or a bioluminescent material. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include Streptavidin/biotin and avidin/biotin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin.

In preferred embodiments, the indicating group is an enzyme, such as horseradish peroxidase (HRP) or glucose oxidase. In such cases where the principal indicating group is an enzyme such as HRP or glucose oxidase, additional reagents are required to visualise the fact that a indicator-moiety/ligand complex (immunoreactant) has formed. Such additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine. An additional reagent useful with glucose oxidase is 2,2'-amino-di-(3-ethyl-benzthiazoline-G-sulfonic acid).

The linking of labels, i.e. labelling of polypeptides such as antibodies, is well known in the art. For instance, proteins can be labelled by metabolic incorporation of radioisotope-containing amino acids provided as a component in the culture medium. See, for example, Galfre et al., *Meth. Enzymol.*, 73:3-46 (1981). The techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas, et al., *Scand. J. Immunol.*, Vol. 8 Suppl. 7:7-23 (1978), Rodwell et al. (1984) *Biotech.* 3:889-894, and U.S. Pat. No. 4,493,795.

Various diagnostic assays employing the above indicator moieties can be set up to test samples for *Campylobacter jejuni*. Exemplary assays are described in detail in *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988. Representative examples of such assays include: countercurrent immuno-electrophoresis (CIEP), radioimmunoassays, radioimmunoprecipitations, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, inhibition or competition assays, and sandwich assays, immunostick (dipstick) assays, simultaneous immunoassays, immunochromatographic assays, immunofiltration assays, latex bead agglutination assays, immunofluorescent assays, biosensor assays, and low-light detection assays (see e.g. also U.S. 4,376,110 and 4,486,530).

In one embodiment, the diagnostic kits of the present invention can be used in an "ELISA" format to detect the quantity of a preselected ligand in a fluid sample. "ELISA" refers to an enzyme-linked immunosorbent assay that employs an antibody

or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen present in a sample and is readily applicable to the present methods. Thus, in some embodiments, an indicator moiety of the present invention can be affixed to a solid matrix to form a solid support that comprises a package in the subject diagnostic systems. A reagent is typically affixed to a solid matrix by adsorption from an aqueous medium although other modes of affixation applicable to polypeptides, such as antibodies, can be used that are well known to those skilled in the art. Useful solid matrices are also well known in the art. Such materials are water insoluble and include the cross-linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals (Piscataway, N.J.); agarose; beads of polystyrene beads about 1 micron to about 5 millimetres in diameter available from Abbott Laboratories of North Chicago, Ill.; polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.

A further diagnostic method may utilise the multivalency of an antibody composition of one embodiment of this invention to cross-link ligands, thereby forming an aggregation of multiple ligands and polypeptides, producing a precipitable aggregate. This embodiment is comparable to the well known methods of immune precipitation. This embodiment comprises the steps of admixing a sample with a composition comprising an antibody of this invention to form a binding admixture under binding conditions, followed by a separation step to isolate the formed binding complexes. Typically, isolation is accomplished by centrifugation or filtration to remove the aggregate from the admixture. The presence of binding complexes indicates the presence of the preselected ligand to be detected.

#### **Binding partners and inhibitors of polypeptides of the invention**

The surface-localisation of the 51 polypeptides to which this invention relates makes them highly suitable as targets for binding partners, such as inhibitors. Surface-located polypeptides of a pathogenic microorganism often interact with the host organism. Thus, any type of binding partner of a surface-located polypeptide may interfere with host-pathogen interaction. Binding partners thus often antagonise the pathogenicity (virulence) of a microorganism. A binding partner may also be an inhibitor of the polypeptide it binds.

Thus, in a further main aspect, the invention relates to methods for the identification of binding partners of the surface-located polypeptides set forth in SEQ ID NO:1-51. Such methods may be biochemical or cell-based.

5      Biochemical methods

In a main aspect, the invention relates to a method for identifying a binding partner of a polypeptide selected from the group consisting of SEQ ID NO:1-36, or a fragment thereof, comprising the steps of

- a. providing a polypeptide selected from the group consisting of SEQ ID NO:1-36, or a fragment thereof,
- 10      b. contacting said polypeptide or fragment with a putative binding partner, and
- c. determining whether said putative binding partner is capable of binding to said polypeptide or fragment.

15      In a preferred embodiment, said putative binding partner is a host-derived molecule.

In further preferred embodiments of the method, the polypeptide or fragment thereof

is provided immobilised on a solid support, such as e.g. a column or microtiter plate,

and, after the contacting step, it is determined whether or not the putative binding

20      partner has bound to the solid support. Immobilisation of the polypeptide or fragment

thereof may be through direct binding to the solid support, or through indirect

binding e.g. using a specific antibody. In preferred embodiments, a washing step is

performed between the contacting step and the determination step, in order to

improve the specificity of detection. In further preferred embodiments, the putative

25      binding partner is complexed with a detectable label. The putative partner may be

labelled before the contacting takes place. Alternatively, labelling may also be

performed after the contacting step. Furthermore, in some embodiments of this

method, immobilisation may be performed after the polypeptide or fragment thereof

has been bound to the binding partner. In preferred embodiments, the method is a

30      screening method wherein the method is repeated for a plurality of putative binding

partners. Suitable methods to determine binding are well-known in the art, and

several of them have been referred to elsewhere herein.

In another aspect, a host-derived binding partner of a polypeptide selected from the

35      group of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID

NO:37-51 may be identified as follows: purified host membranes are electrophoretically separated, blotted over to a membrane and incubated with the polypeptide of interest or fragment thereof. Binding can then be detected using antibodies specific for the polypeptide of interest or fragment thereof. The host 5 binding partner to which the polypeptide or fragment thereof has bound can subsequently be identified by elution from the blot and subsequent analysis by mass spectrometry, or by any other technique known in the art.

If the binding partner of a surface-located polypeptide of a pathogenic organism is a host-derived molecule, then such an interaction between the surface-10 located polypeptide and the host may be important for the virulence of the bacterium. Compounds that interfere with the interaction of the surface-located polypeptide and the host-derived binding partner may thus be suitable for prevention or treatment of *Campylobacter jejuni* infections. Accordingly, another method of the invention relates to a method of identifying an inhibitor of the interaction of any of the 15 surface-located *Campylobacter jejuni* polypeptides of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, with a host-derived binding partner comprising the steps of:

- a. providing any of the polypeptides of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, or a fragment thereof,
- b. providing a host-derived binding partner of said polypeptide (identified as described above or by any other method),
- c. contacting said polypeptide with said host-derived binding partner in the absence of a putative inhibitor of said interaction,
- d. contacting said polypeptide with said host-derived binding partner in the 25 presence of said putative inhibitor,  
and
- e. determining whether the strength of the binding of said polypeptide to said host-derived binding partner resulting from step d. is reduced as compared to that resulting from step c.

30 In some embodiments, step c. and d. may be performed in two different sample compartments. In other embodiments, step d. may be performed by adding the putative inhibitor to the mixture of step c. In preferred embodiments, the method is repeated for a plurality of putative inhibitors.

Of particular interest are binding partners that inhibit an activity of a surface-located polypeptide. Such activity may be enzymatic activity, transport activity, or any type of other biochemical or cellular activity, preferably enzymatic activity.

Preferred host-derived binding partners are host polypeptides and host 5 lipids. Binding may e.g. be determined as described by Szymanski and Armstrong (1996) *Infect. Immun.* 64:3467-3474.

In preferred embodiments of the above described biochemical methods, the binding between the binding partner and the surface-located polypeptide or fragment thereof has a dissociation constant or  $K_d$  of less than  $5 \times 10^{-6} M$ , such as 10 less than  $10^{-6} M$ , e.g. less than  $5 \times 10^{-7} M$ , such as less than  $10^{-7} M$ , e.g. less than  $5 \times 10^{-8} M$ , such as less than  $10^{-8} M$ , e.g. less than  $5 \times 10^{-9} M$ , such as less than  $10^{-9} M$ , e.g. less than  $5 \times 10^{-10} M$ , such as less than  $10^{-10} M$ , e.g. less than  $5 \times 10^{-11} M$ , such as less than  $10^{-11} M$ , e.g. less than  $5 \times 10^{-12} M$ , such as less than  $10^{-12} M$ . Dissociation constants can e.g. be determined by surface plasmon resonance analysis.

15

#### Cell-based methods

Reducing the level of a surface-located polypeptide, by deletion or disruption of the structural gene for it or by down-regulating gene expression (see below), may affect a bacterial cell. The cell may become more sensitive to cytotoxic compounds.

20 Especially for surface-located polypeptides, a reduction of their level may affect the function of the cell's exterior parts, such as the outer membrane or cell wall, in preventing compounds of entering the cell. Thus, reduction of the level of an surface-located polypeptide can make a cell more 'permeable' for various compounds.

25

Thus, an aspect of the present invention relates to a method for identifying a compound with antibacterial activity against *Campylobacter jejuni* comprising the steps of

- 30 a. providing a sensitised cell which has a reduced level of any of the polypeptides of SEQ ID NO:1-36, and
- b. determining the sensitivity of said cell to a putative antibacterial compound, for instance by a growth assay.

Preferably, the method is a screening method wherein the procedure is repeated for a plurality of putative antibacterial compounds. Preferred putative antibacterial 35 compounds are ones that do not pass through the outer membrane of a wild-type *Campylobacter jejuni* cell.

Furthermore, the invention relates to a method for identifying a compound with antibacterial activity against *Campylobacter jejuni* comprising the steps of

- a- providing a sensitised cell which has a reduced level of any of the polypeptides  
5 of SEQ ID NO:37-51, and
- b. determining the sensitivity of said cell to a putative antibacterial compound, for instance by a growth assay, wherein the putative antibacterial compound is not capable of passing through the outer membrane of a wild-type *Campylobacter jejuni* cell.

10 Preferably, the method is screening method wherein the procedure is repeated for a plurality of putative antibacterial compounds.

The rationale behind this approach is that a cell with a lower level of the surface-located polypeptide will exhibit increased sensitivity to cytotoxic compounds, 15 allowing identification of antibacterial compounds with low potency that are missed when using wild-type cells for the assay. Compounds identified by this method will be often need to be modified in order to improve potency. This can be done by chemical modification.

20 Inhibition of the activity of a surface-located polypeptide may affect the viability (i.e. survival, growth and/or proliferation) of the bacterium. Of particular interest is inhibition of surface-located polypeptides that are essential for viability of *Campylobacter jejuni*. Essentiality of a *Campylobacter jejuni* gene may e.g. be investigated as described in WO 02/077183. Inhibitors of essential surface-located

25 polypeptides may not need to enter the bacterial cell to be able to affect its viability. Thus, generally fewer requirements are posed on the structure of an inhibitor of an essential surface-located target polypeptide than on an inhibitor of an intracellular target, to be effective as an antibacterial agent.

30 Accordingly, the invention relates to a method for identifying an inhibitor of a polypeptide selected from the group consisting of SEQ ID NO:1-36, comprising the steps of

- a. providing two cells which differ in the level of any of the polypeptides of SEQ ID NO:1-36,
- 35 b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and

- c. determining whether said two cells are differently affected by the presence of said putative inhibitor.

Preferably, the method is repeated for a plurality of putative inhibitors. Preferred inhibitors are ones that do not pass through the outer membrane of a

5 Campylobacter jejuni cell.

Furthermore, the invention relates to a method for identifying an inhibitor of a polypeptide selected from the group consisting of the polypeptides of SEQ ID NO:37-51, comprising the steps of

- 10 a. providing two cells which differ in the level of any of the polypeptides of SEQ ID NO:37-51,
- b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, wherein the putative inhibitor is not capable of passing through the outermembrane of a Campylobacter jejuni cell, and
- 15 c. determining whether said two cells are differently affected by the presence of said putative inhibitor.

Preferably, the method is repeated for a plurality of putative inhibitors.

The rationale behind this approach is that the viability of a cell with a lower activity of the essential polypeptide will be more affected by an inhibitor of the polypeptide than the viability of the cell with a higher level. If the two cells are differently affected, this is an indication that the inhibitor acts on the target or at least in the same biochemical pathway.

25 In some embodiments of the method, the two cells with different activity of the polypeptide of interest are a wild-type cell (or other cell with wild-type activity of the gene of interest) and a sensitised cell with a reduced activity of the polypeptide of interest. In some embodiments, the different or reduced level in the sensitised cell can be a different or reduced expression level of the gene of interest (resulting in a

30 different or reduced copy number of the polypeptide). This can be accomplished by putting the gene under control of a regulatable promoter or by regulatable expression of an antisense RNA which inhibits translation of an mRNA encoding the essential polypeptide. In other embodiments, the different or reduced activity can be a different or reduced activity of the polypeptide of interest, e.g. due to a mutation,

35 such as a temperature-sensitive mutation.

Suitable ways of generating sensitised cells and of using these in screening for inhibitors have been described in WO 02/077183. Sensitised cells may be obtained by growing a conditional-expression *C. jejuni* mutant strain in the presence of a 5 concentration of inducer or repressor or other conditions which provide a level of a gene product required for bacterial viability such that the presence or absence of its function becomes a rate-determining step for viability. Regulatable promoters for *Campylobacter jejuni* have e.g. been described in Kelana et al. (2003) J Food Prot 66:1190-1197 and Dedieu et al. (2002) Appl Environ. Microbiol. 68:4209-4215. The 10 sub-lethal expression of the target gene may be such that growth inhibition is at least about 10%, such as at least about 25%, e.g. at least about 50%, such as at least about 75%, e.g. at least 90%, such as at least 95%.

In another embodiment of the cell-based assays of the present invention, sensitised 15 cells are obtained by reduction of the level activity of a polypeptide required for bacterial viability using a mutation, such as a temperature-sensitive mutation, in the polypeptide. Growing such cells at an intermediate temperature between the permissive and restrictive temperatures produces cells with reduced activity of the gene product. It will be appreciated that the above method may be performed with 20 any mutation which reduces but does not eliminate the activity or level of the gene product which is required for bacterial viability. This approach may also be combined with the conditional-expression approach. In this combined approach, cells are created in which there is a temperature-sensitive mutation in the gene of interest and in which this gene is also conditionally-expressed.

25 When screening for inhibitors of an essential polypeptide, growth inhibition can be measured by directly comparing the amount of growth, measured by the optical density of the culture relative to uninoculated growth medium, in an experimental sample with that of a control sample. Alternative methods for assaying cell 30 proliferation include measuring green fluorescent protein (GFP) reporter construct emissions, various enzymatic activity assays, and other methods well known in the art. Other parameters used to measure viability include e.g. colony forming units. The above method may be performed in solid phase, liquid phase, a combination of the two preceding media, or *in vivo*. Multiple compounds may be transferred to agar 35 plates and simultaneously tested using automated and semi-automated equipment.

Cell-based assays of the present invention are capable of detecting compounds exhibiting low or moderate potency against the target molecule of interest because such compounds are substantially more potent on sensitised cells than on non-sensitised cells. The effect may be such that a test compound may be two to several times more potent, e.g. at least 10 times more potent, such as at least 20 times more potent, e.g. at least 50 times more potent, such as at least 100 times more potent, e.g. at least 1000 times more potent, or even more than 1000 times more potent when tested on the sensitised cells as compared to non-sensitised cells.

10

A mutant *Campylobacter jejuni* strain that overexpresses a surface-located polypeptide can also be used to identify a compound that inhibits such a polypeptide. If the compound is cytotoxic, overexpression of the target polypeptide can make cells more resistant. Thus, the invention also relates to a method for finding an inhibitor of any of the surface-located *Campylobacter jejuni* polypeptides of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51 comprising the steps of

- 15 a. providing two cells which differ in the activity of any of the surface-located *Campylobacter jejuni* polypeptides of SEQ ID NO:1-51, such as any of SEQ ID NO:1-36 or any of SEQ ID NO:37-51, wherein one cell contains a substantially wild-type copy number of said polypeptide and the other cell contains higher than wild-type copy number of said polypeptide,
- 20 b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and
- 25 c. determining whether or not said two cells are differently affected by the presence of said putative inhibitor.

Overexpression may be achieved using strong promoters or by introducing multiple copies of the structural gene for a surface-located polypeptide. Strong *Campylobacter jejuni* promoters have been described by Wosten et al. (1998) J. Bacteriol. 180:594-599. As also overexpression of polypeptides that are not the cellular target of an inhibitor can make cells resistance to an inhibitor, inhibition of the target polypeptide of interest by a putative inhibitor will need to be verified by other means, such as e.g. a biochemical assay.

30 In addition to inhibitors of a biochemical or other cellular activity of a surface-located polypeptide, the cellular methods described above can be used to

identify compounds that reduce the expression level of a target, and thereby its copy number, e.g. by interfering with gene regulation.

5 In preferred embodiments of the any of the cell-based- or biochemical methods for finding binding partners or inhibitors, the method is repeated for a plurality of candidate compounds.

10 In a further aspect, the invention relates to the mutant *Campylobacter jejuni* strains used in the cell-based methods described herein, such as strains in which the gene encoding the surface-located polypeptide is placed under the control of a heterologous regulatable promoter, strains carrying temperature-sensitive alleles of the surface-located polypeptides, and strains overexpressing the surface-located polypeptides.

15 Other methods of interfering with bacterial growth by targeting surface-located polypeptides, such as any of the polypeptides of SEQ ID NO:1-36 include suppression of gene expression using specific antisense molecules, such antisense RNA or DNA, and using ribozyme molecules specific for mRNA encoding the essential surface-located polypeptides.

**Examples****Strategy:**

The experimental steps in the project as follows: Isolate surface proteins by low pH 5 elution. Analyse by 2-D gels and mass spectrometry. Clone into *E. coli* expression vector. Produce recombinant protein, immunise mice, challenge the immunised mice with *Campylobacter jejuni* and look for protection against disease and intestinal colonisation. *E. coli* and *Salmonella* surface localisation is also assessed (if positive, there is potential for use in attenuated vector strains).

10

**Bacterial culture:**

*Campylobacter jejuni* (C.j.) strain ML53 (serotype 0:19), a clinical isolate from human faeces, was donated by Karen Krogfeld (SSI). It was routinely grown on blood agar plates at 37°C in atmosphere of 10% CO<sub>2</sub>, 5% O<sub>2</sub>.

15

**Surface proteins extraction:**

Bacteria were grown overnight on blood agar plates, harvested into 50 mM Tris pH7.8 and pelleted by centrifugation at 6000g for 5 minutes. The pellet was resuspended in 0.2 M glycine pH2.2 and the bacterial suspension was gently mixed at 20 room temperature for 10 minutes. Bacteria were pelleted again by centrifugation at 6000g for 5 minutes, supernatant containing surface proteins was collected, neutralised with NaOH and frozen at -80°C. The sample was desalted on Amersham Hi-Trap desalting column before 2-D gel electrophoresis.

25

**2-D gel electrophoresis:**

Two-dimensional gel electrophoresis was performed either on the Ettan Dalt 2 system (Amersham Biosciences) or on the Novex NuPage system (Invitrogen) according to the manual provided with the gel system.

In brief: First dimension runs were performed on either 7 cm or 24 cm pre-cast IPG

30

strips (pH range 3-10 or 6-11) using the Ettan IPGphor isoelectric focusing system (Amersham Biosciences) according to the manufacturer's instructions. Isofocusing was performed at the following conditions: 7 cm pH 3-10 strips:8000 Vh, 7 cm pH 6-11 strips:16000Vh, 24 cm pH 3-10 strips: 52000Vh. The second dimension was performed using pre-cast 12.5 % gels (Amersham Biosciences) at 5W per gel for 15 min then total 170 W for 4-6 hours for 24 cm strips. The 7 cm strips were run on the

35

Novex NuPage system (Invitrogen) using pre-cast 4-12% gels (Invitrogen) at 200 volts for 40 minutes. Gels were silver stained according to a modified method described originally by Mortz et al. (2001) *Proteomics* 1(11), 1359-1363, and spots for mass spec analysis were picked using the Ettan Spot Picker from Amersham according to the manufacturer instructions.

**5 Mass Spectrometry:**

Specific protein spots were spot-picked, and placed in Milli-Q water. These gel plugs were washed in 50mM NH<sub>4</sub>HCO<sub>3</sub> / 50% ethanol and dehydrated by incubation in 10 96% ethanol. Reduction and alkylation was performed by incubating in reducing solution (10 mM DTT, 50 mM NH<sub>4</sub>HCO<sub>3</sub>) at 56°C followed by a room temperature incubation in alkylation solution (55 mM iodoacetamide, 50 mM NH<sub>4</sub>HCO<sub>3</sub>) in the dark. Two cycles of washing and dehydration were then performed prior to the addition of 5 ul trypsin solution (12.5 ng/ul Promega trypsin in 50 mM NH<sub>4</sub>HCO<sub>3</sub>, 10% 15 Acetonitrile). Then an additional amount of sodium bicarbonate solution was added and the digests were incubated overnight at 37°C. Trifluoroacetic acid was added to the overnight digest followed by incubation with shaking.

Parts of the extract were used in MALDI-TOF peptide mass fingerprint analysis (Reflex IV, Bruker Daltonics, Germany) and the peaklist was used in data-20 base searching against a specific *Campylobacter jejuni* database. The Mascot search program and scoring algorithm (Matrix Science, UK) was used in database searching. Peptide mass tolerance was set to 60 ppm and 0.5 Da, respectively. Search parameters were adjusted to include oxidation of Met, the addition of Carbamidomethyl groups to Cys, and trypsin was allowed to miss one cleavage site per 25 peptide.

The fragments that were identified are given in List 1 of Danish priority application PA 2003 01726, filed November 21, 2003 and List 1 of US provisional application 60/524,617, filed November 25, 2003 (incorporated by reference) were identified. In total 51 different *Campylobacter jejuni* proteins were identified using 30 this procedure. The full-length sequences of these proteins are given in SEQ ID NO:1-51 (see figure 4). The proteins in the sequence listing are functionally classified according to the classification from the Sanger Institute. All proteins which were predicted from genomic sequence but had not been characterised before, and did not have any homology to previously characterised proteins, were classified as hypothetical by the Sanger institute. Those which had homology to known proteins 35

were named as the corresponding known protein with the pre-fix “probable” or “putative”, depending on the degree of homology. Some proteins have small motifs, which did not allow to assign a precise biochemical/metabolic function to them, but did allow to state the fact that they possess of a certain feature, such as nucleotide 5 binding motifs, membrane attachment sites, etc. Putative periplasmic proteins were classified as such on a similar basis – they possess a short (4-6 amino acids) N-terminal motif, which may mediate transport to the periplasm.

**Bioinformatic studies:**

10 Antigenicity index studies were performed using the default parameters determined using Lasergene sequence analysis software from the company DNASTar (Burland, TG (2000) Methods Mol. Biol. 132:71-91). The sequences set forth in SEQ ID NO:52-119 are predicted to be particularly antigenic fragments of their corresponding full-length polypeptides (see figure 4).

15

**Cloning and expression in *E. coli*:**

Genes corresponding to the proteins of interest were PCR amplified and cloned into an *E. coli* expression vector containing his-tag (pET101, Invitrogen). Resulting plasmids were transformed into *E. coli* BL21(DE3) strain and protein expression was 20 induced with 0.5 mM IPTG for 4 hours. Glycine eluate was prepared as above and analysed for the presence of the recombinant *Campylobacter jejuni* protein by three independent methods: Coomassie staining, Western blotting with anti-his tag antibody, and mass spec analysis. Surface localisation detection was carried out for eight plasmids (the ones expressing Cj0092, Cj0143c, Cj0420, Cj0715, Cj0772c, 25 Cj1018c, Cj1380 and Cj1643) All eight proteins were found on the cell-surface of *E. coli*.

Recombinant protein was purified from cultures grown and induced as described above using NTA-Ni agarose (Qiagen) according to the manufacturer’s instructions.

30 Purified proteins were dialyzed against PBS and kept frozen at -80.

**Mouse immunization***Antigen dose determination.*

To determine optimal immunization doze and vaccination time schedule for each 35 protein, mice were immunized with 1, 5, 10 and 25 microgram of each protein. Ap-

properiate amount of protein dissolved in PBS was mixed with 100 µg alum (Alhydrogel, Brenntag Biosector) /mice and rotated at room temperature for 30 minutes. Volume was adjusted to 0.5 ml with PBS. Mice were immunized subcutaneously 3 times (day 0, 14, 28). Bleeds were taken on day 0 and 7 days after each immunization (day 7, 21, 35). A blood sample of 200 µl blood ml was drawn from the retro orbital plexus at day 7, left for 1 hour to coagulate, centrifuged for 10 min at 3500g, and serum was collected.

#### Bleed analysis

10 Antibody response was monitored by determining the antibody titer in the bleeds. This was done by Western blots. Serum was serially diluted in PBS/0.1% Tween from 1:100 to 1:25600. Recombinant protein was run on preparative (2-D) well gels (Invitrogen) so that 1.5 mm of the protein band on the membrane would correspond to 100 ng of the protein. Surf-Blot apparatus with 1.5 mm wide slots (Idea Scientific, 15 Minneapolis, MN) was used to perform Western blotting. Serum dilutions were used as primary antibody and alkaline phosphatase conjugated anti-mouse antibodies (Sigma) were used as secondary antibody. Blots were developed with FastTab tablets (Sigma). All antigens were detectable at an antiserum dilution between 12800 and 25600 when applied at 5, 10 and 25 microgram/animal.

20

#### *Immunization for challenge*

Mice were immunized with 25 microgram of recombinant protein vaccine prepared as above, on days 0,14 and 28. Bleeds were taken on days 7, 21 and 35 and tested as above. Mice, which were not used for challenge experiments within two weeks 25 from the last boost, were boosted again with 10 microgram of recombinant protein one week before the challenge.

#### **Mouse oral challenge**

30 *Campylobacter jejuni* strains ML1 and ML53 (clinical isolates donated by Karen Krogfeld, SSI) were grown o/n on blood agar plates at 42°. The day before challenge, bacteria were harvested into Brain heard infusion broth containing 1% yeast extract and diluted to OD<sub>600</sub> 0.05 to obtain a starter culture. 75cm<sup>2</sup> flasks containing 20ml of BHI agar were seeded with 25ml of the starter culture and incubated overnight at 42°. On the day of challenge, bacteria were harvested by centrifugation at 35 6000g for 5 minutes and resuspended in fresh BHI/YE broth to OD<sub>600</sub> 1 (5x10<sup>8</sup> to 10<sup>9</sup>

colony forming units (cfu)/ml; actual cfu was determined for each batch by plating serial dilutions on BHI agar plates). Suspension was kept on ice until it given to mice (usually within 3 hours of preparation).

5 6-8 vaccinated mice per antigen were challenged orally with 2.5-5x10<sup>8</sup>cfu of *Campylobacter jejuni* (0.5ml of the suspension prepared as above). Five faecal pellets (or all faecal pellets in ACE017 experiment) were collected each day, placed into 0.5ml (or 5ml) of BHI/YE broth supplemented with 10% glycerol and frozen at -80°.

10 Colonization was monitored by plating on selective media for *Campylobacter*. Faecal pellets were homogenized, volume adjusted to 2 (or 12) ml, and 250ul of the homogenate was placed into 1.5 ml of BHI/YE broth on top of the blood agar plate. Plates were incubated at 42° for 2-3 hours, and 150-250ul of the liquid was spread on Karmali agar plates, which were then incubated at 42° for 48 hours. Plates were

15 scored as follows: a score of 1000 was assigned if confluent lawn was observed, a score of 500 if separate colonies were distinguishable in the lawn, and a score of 0-100, if the colony number was below 100 (colonies were counted in that case). Score was averaged across all mice for every antigen on every day.

20 **Strain screening**

13 strains of *Campylobacter jejuni* and one strain of *Campylobacter coli* were screened for the presence of the 8 antigens used in mouse challenge experiments. Whole cell lysed was run on SDS gel and Western blotted with antisera from immunized mice.

25

**Results:**

Five experiments including different combinations of antigens and controls were performed as listed below:

30	Experiment name	Antigens used
	ACE003b	Cj0092, Cj0143c, Cj0420, Cj0772c, alum
	ACE003c	Cj0715, Cj1018c, Cj1380, Cj1643, alum
	ACE011a	Cj0092, Cj0143c, Cj0420, Cj0772c, alum
	ACE011b	Cj0715, Cj1018c, Cj1380, Cj1643, alum

ACE017 Cj0092, Cj0143c, Cj0420, Cj0772c, Cj1018c, Cj1380, Cj1643, cellulose-binding domain from Clostridium cellulovorans (CBP, Sigma Alrich C8581), glycine eluate from C.j. strains ML1 and ML53.

5 Example of bleed analysis performed on bleeds from mice from experiments ACE003b and ACE003c are presented on figures 1 and 2.

Results of challenge are presented in Figure 3.

10 Results of screening for the presence of antigens in different Campylobacter strains are presented in table 1.

DNA sequencing of ACE 393 from the ML53 (serotype 0:19) strain:

15 The DNA sequencing of ACE 393 (SEQ ID NO:120) from strain ML53 revealed 3 differences compared to the published sequence at NCBI on the amino acid level after translating into the protein sequence.

The differences were the following:

Position 70 of the amino acid sequence: V (public sequence) to A (ML53 strain)

Position 136 of the amino acid sequence: A (public sequence) to T (ML53 strain)

20 Position 168 of the amino acid sequence: T (public sequence) to A (ML53 strain)

25 An experimental verification of the protein sequence of recombinant ACE 393 from the strain ML53 (0:19) that was used for the initial animal efficacy studies was carried out. The analysis included: Intact mass determination by MALDI-TOF; 1D Gel analysis; 2D Gel analysis and 2D Gel western blot. The data (not shown) was based on the initial construct, that is, the sequence including a C-terminal 6 His-tag and a V5-linker region. All assays and analyses were conducted with ACE 393 obtained after Ni-His purification according to standard protocols.

30 From the intact analysis of ACE 393 two proteins were seen. These two masses matched perfectly the predicted mass of an N-terminal truncated form (- 21 amino acids and a similar N-terminal truncated form with additional C-terminal truncation of 19 amino acids. 1D SDS PAGE showed two spots one major and one minor. This corresponded well with the data from the intact MALDI-TOF analysis. The peptide mapping data from these two spots did not show any difference possibly due to overloading. The numbers of spots on 2D gel analysis indicated that the mixture

might contain more than two components. The data indicated that the changes might be due to differences in charge due to the number of SDS molecules. Western blot data using the mouse antibodies gave the same pattern and fitted well with the silver stain data.

5

**MALDI-TOF peptide fingerprint analysis of native and recombinant ACE 393****Native-form**

The native form of ACE 393 was found in 4 different 2D gels containing whole *Campylobacter* cell lysate. The identification was based on MALDI-TOF peptide finger-  
print analysis with a sequence-coverage of 40 to 55%.

The MALDI-TOF peptide fingerprint data was searched against both the public se-  
quence and the ACE-393 in-house found sequence (ML53, 0:19). The in-house se-  
quence gave two additional peptides:

131-143                   **DIVLDTEIGGVAK** (SEQ ID NO:121)

15   166-190                   **FAASTSTITLSDDINLNIEVEANEK** (SEQ ID NO:122)

(Amino acids in bold are the differences between the two sequences)

The peptide containing the last modification compared to the public sequence (68-  
73; **LDATIK** (SEQ ID NO:123)) is too small to be found by MALDI-TOF peptide fin-  
gerprint analysis.

20   ***Recombinant form***

MALDI-TOF peptide fingerprint analysis of the recombinant protein revealed the  
same two modifications as found in the analysis of the native protein. Additional  
peptides were identified from the linker-His sequence.

25   **Hypervariable regions**

Target sequences were checked against potential hypervariable and homopolymeric  
regions described in "The genome sequence of the food-borne pathogen *Campylo-  
bacter jejuni* reveals hypervariable sequences. *Nature*. 2000 Feb 10;403(6770):665-  
8." The targets described herein were not found in these variable regions, thus mak-  
ing them particularly suitable as vaccine candidates.

**Claims****1. A composition comprising**

- a polypeptide which comprises a sequence selected from the group consisting of surface-located *Campylobacter* polypeptides of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide,
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector, or
- an antibody capable of binding said polypeptide,  
for use as a medicament.

**2. The composition of claim 1, wherein the composition comprises**

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector.

**3. The composition of any of the preceding claims, wherein the variant has at least 95%, such as at least 96%, e.g. at least 97%, such as at least 98%, e.g. at least 99% sequence identity to said sequence.****4. The composition of any of the preceding claims, wherein the antigenic fragment comprises less than 99%, such as less than 75%, e.g. less than 50%, such as less than 25%, e.g. less than 20%, such as less than 15%, or e.g. less than 10% of the full-length of said sequence.****5. The composition of any of the preceding claims, wherein the antigenic fragment comprises less than 70 consecutive amino acid residues, e.g. less than 50, such as less than 40, e.g. less than 30, such as less than consecutive 20 residues of said sequence.**

6. The composition of any of the preceding claims, wherein the antigenic fragment comprises 6 or more, such as 7 or more, e.g. 8 or more, such as 9 or more, e.g. 10 or more consecutive amino acids of said sequence.

5

7. The composition of any of the preceding claims, wherein the antigenic fragment comprises one or more residues of a fragment selected from the group consisting of SEQ ID NO:52-119, e.g. two or more consecutive, such as three or more consecutive, e.g. four or more consecutive, such as 5 or more consecutive 10 residues, e.g. 6 or more consecutive residues of a fragment selected from the group consisting of SEQ ID NO:52-119.

10

8. The composition of any of the preceding claims, wherein the polypeptide comprises a tag, such as a histidine tag.

15

9. The composition of any of the preceding claims, wherein the recombinant cell is an attenuated or reduced-virulence *Escherichia coli* cell or an attenuated or reduced-virulence *Salmonella* cell.

20

10. The composition of any of the preceding claims, wherein the recombinant cell is alive.

11. The composition of any of the preceding claims, wherein the recombinant cell is dead.

25

12. The composition of any of claims 2-11, wherein the medicament is a vaccine.

30

13. The composition of claim 12, wherein the composition comprises an immunogenic carrier, such as a carrier protein, wherein the immunogenic carrier preferably is bound to said polypeptide.

14. The composition of any of claims 12-13, wherein the composition comprises an adjuvant.

15. The composition of claim 1, wherein the composition comprises an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:1-36.
- 5       16. The composition of claim 15, wherein the antibody furthermore is capable of binding an intact *Campylobacter jejuni* cell.
17. The composition of claim 1, wherein the composition comprises an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:37-51 and capable of binding an intact *Campylobacter jejuni* cell.
- 10
18. The composition of any of claims 15 to 17, wherein the antibody is polyclonal.
19. The composition of any of claims 15 to 17, wherein the antibody is monoclonal.
- 15
20. The composition of any of claims 15 to 19, wherein the antibody is a human antibody or humanised antibody.
21. The composition of any of claims 15 to 20, wherein the antibody is a binding fragment of an antibody.
- 20
22. The composition of any of claims 15 to 21, wherein the antibody has a dissociation constant or Kd less than  $5 \times 10^{-6}$ M, such as less than  $10^{-6}$ M, e.g. less than  $5 \times 10^{-7}$ M, such as less than  $10^{-7}$ M, e.g. less than  $5 \times 10^{-8}$ M, such as less than  $10^{-8}$ M, e.g. less than  $5 \times 10^{-9}$ M, such as less than  $10^{-9}$ M, e.g. less than  $5 \times 10^{-10}$ M, such as less than  $10^{-10}$ M, e.g. less than  $5 \times 10^{-11}$ M, such as less than  $10^{-11}$ M, e.g. less than  $5 \times 10^{-12}$ M, such as less than  $10^{-12}$ M, e.g. less than  $5 \times 10^{-13}$ M, such as less than  $10^{-13}$ M, e.g. less than  $5 \times 10^{-14}$ M, such as less than  $10^{-14}$ M, e.g. less than  $5 \times 10^{-15}$ M, or less than  $10^{-15}$ M.
- 25
- 30
23. The composition of any of the preceding claims, wherein the composition comprises a pharmaceutically-acceptable carrier.
24. The composition of any of the preceding claims, wherein the composition is suitable for systemic administration.
- 35

25. The composition of any of the preceding claims, wherein the composition is suitable for intravenous, intramuscular, or subcutaneous administration.

5 26. The composition of any of the preceding claims, wherein the composition is suitable for oral administration.

27. The composition of any of the preceding claims, wherein the composition is suitable for intranasal administration.

10

28. An antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:1-36.

15

29. The antibody of claim 28, wherein the antibody furthermore is capable of binding an intact *Campylobacter jejuni* cell.

30. An antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:37-51 and capable of binding an intact *Campylobacter jejuni* cell.

20

31. The antibody of any of claims 28 to 30, comprising the features of any of claims 18 to 22.

25

32. A recombinant cell transformed or transfected with a polynucleotide comprising a sequence encoding a polypeptide, said polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1-36, or comprising an antigenic fragment or variant of said sequence.

33. The recombinant cell of claim 32, wherein the recombinant host cell is an *Escherichia coli* or *Salmonella* cell.

30

34. The recombinant cell of claim 32 or 33, wherein recombinant the cell is an attenuated or reduced-virulence cell.

35

35. A recombinant attenuated or reduced-virulence *Escherichia coli* or recombinant attenuated or reduced-virulence *Salmonella* cell transformed or transfected with

a polynucleotide comprising a sequence encoding a polypeptide, said polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:37-51, or comprising an antigenic fragment or variant of said sequence.

5 36. Use of

- a polypeptide which comprises a sequence selected from the group consisting of SEQ ID NO:1-51, or comprises an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,
- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

for the preparation of a medicament for the immunisation of an animal or human being against *Campylobacter*, preferably *Campylobacter jejuni*, infections.

15

37. The use of claim 36, wherein the immunisation induces a protective immune response.

20

38. The use of claim 36 or 37, wherein the medicament is a medicament suitable for parenteral, intravenous, intramuscular, subcutaneous, oral or intranasal administration.

25

39. Use of an antibody capable of binding a polypeptide selected from the group consisting of SEQ ID NO:1-51, preferably an antibody as defined in any of claims 28 to 31, for the manufacture of a medicament for the treatment or prevention of *Campylobacter*, preferably *Campylobacter jejuni*, infections in an animal or human being.

30

40. A method for raising antibodies to a polypeptide selected from the group consisting of SEQ ID NO:1-36 in a non-human animal comprising the steps of

a. providing

- a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:1-36, or comprising an antigenic fragment or variant of said sequence,
- a polynucleotide comprising a sequence encoding said polypeptide,

- an expression vector comprising a sequence encoding said polypeptide, or
- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

5 b. introducing a composition comprising said polypeptide, polynucleotide, vector, recombinant virus or recombinant cell into said animal,

c. raising antibodies in said animal, and

d. isolating and optionally purifying the antibodies.

10 41. A method for raising antibodies to a polypeptide selected from the group consisting of SEQ ID NO:37-51 in a non-human animal, wherein the antibodies are capable of binding an intact *Campylobacter jejuni* cell, the method comprising the steps of

a. providing

15 - a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:37-51, or comprising antigenic fragment or variant of said sequence,

- a polynucleotide comprising a sequence encoding said polypeptide,

- an expression vector comprising a sequence encoding said polypeptide,

20 or

- a recombinant virus or recombinant cell comprising said polynucleotide or said expression vector,

b. introducing a composition comprising said polypeptide, polynucleotide, vector, recombinant virus or recombinant cell into said animal,

25 c. raising antibodies in said animal,

d. isolating and optionally purifying the antibodies, and

e. selecting antibodies capable of binding an intact *Campylobacter jejuni* cell.

42. The method of claim 40 or 41, wherein the animal is a transgenic animal capable

30 of producing human antibodies.

43. A method for detecting *Campylobacter jejuni* or parts thereof in a sample comprising the steps of

- a. contacting said sample with an indicator moiety capable of specifically binding a polypeptide selected from the group consisting of SEQ ID NO:1-36, and
- b. determining whether a signal has been generated by the indicator moiety, thereby detecting whether said sample contains *Campylobacter jejuni* or parts thereof.

5

44. The method of claim 43, wherein the indicator moiety furthermore is capable of binding intact *Campylobacter jejuni* cells.

10

45. A method for detecting *Campylobacter jejuni* in a sample comprising the steps of
  - a. contacting said sample with an indicator moiety capable of specifically binding a polypeptide selected from the group consisting of SEQ ID NO:37-51, wherein the indicator moiety furthermore is capable of specifically binding intact *Campylobacter jejuni* cells, and
  - b. determining whether a signal has been generated by the indicator moiety, thereby detecting whether said sample contains *Campylobacter jejuni*.

15

46. The method of any of claims 43 to 45, wherein said indicator moiety does not pass through the outer membrane of a *Campylobacter jejuni* cell.

20

47. The method of any of claims 43 to 46, wherein said indicator moiety consist of or comprises an antibody, such as an antibody as defined in any of claims 28 to 31.

25

48. A method for identifying a binding partner of a polypeptide selected from the group consisting of SEQ ID NO:1-36 or a fragment thereof, comprising the steps of
  - a. providing a polypeptide selected from the group consisting of SEQ ID NO:1-36 or a fragment thereof,
  - b. contacting said polypeptide or fragment with a putative binding partner, and
  - c. determining whether said putative binding partner is capable of binding to said polypeptide or fragment.

30

49. A method for identifying a compound with antibacterial activity against *Campylobacter jejuni* comprising the steps of

35

- a. providing a sensitised cell which has a reduced level of a polypeptide selected from the group consisting of SEQ ID NO:1-36, and
- b. determining the sensitivity of said cell to a putative antibacterial compound, for instance by a growth assay.

5

50. A method for identifying a compound with antibacterial activity against *Campylobacter jejuni* comprising the steps of

- a. providing a sensitised cell which has a reduced level of a polypeptide selected from the group consisting of SEQ ID NO:37-51, and

10

- b. determining the sensitivity of said cell to a putative antibacterial compound, for instance by a growth assay, wherein the putative antibacterial compound is not capable of passing through the outer-membrane of a wild-type *Campylobacter jejuni* cell.

15

51. A method for identifying an inhibitor of a polypeptide selected from the group consisting of SEQ ID NO:1-36, comprising the steps of

- a. providing two cells which differ in the level of a polypeptide selected from the group consisting of SEQ ID NO:1-36,
- b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, and
- c. determining whether said two cells are differently affected by the presence of said putative inhibitor.

20

52. The method of claim 51, wherein the putative inhibitor does not pass through the outer membrane of a *Campylobacter jejuni* cell.

25


53. A method for identifying an inhibitor of a polypeptide selected from the group consisting of the polypeptides of SEQ ID NO:37-51, comprising the steps of

30

- a. providing two cells which differ in the level of a polypeptide selected from the group consisting of SEQ ID NO:37-51,
- b. determining the sensitivity of said cells to a putative inhibitor, for instance by a growth assay, wherein the putative inhibitor is not capable of passing through the outer membrane of a *Campylobacter jejuni* cell, and
- c. determining whether said two cells are differently affected by the presence of said putative inhibitor.


35

Fig. 1






2/20

Fig. 2




3/20

Fig. 3






4/20

Fig. 3





5/20

Fig. 3






6/20

Fig. 3




7/20

Fig. 3




8/20

Fig. 3



9/20

Fig. 3



10/20

Fig. 3






FIG. 4

11/20

## Sequence listing

SEQ ID NO:1

ACE83 Cj0092

>AnrP630851 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKILFIGSLVMASLLYAQGSQPVEITQQDINTQNEMSDASTKDITPKSIEDFFEEFADNFGIEYGITKD  
 GKTFYTGKSTVAVNDTDPQFAQALQNAYQKAMLNLQSEFIRDAFGRIATSKIQNYEADNSTNAKEFDELP  
 KGDKVQDQILNKLTLQLAGAQLDKALDKDGLIDTNLSLEDRKKTLLKQEFLNKTMNAIGSMSGLVPVQTIVT  
 QRRGEYDVGVVAVISNKTRQLAKDMALARQSAIKGKGKAISEYLPKDTKGFLNEBYGIRLVYDENGAPIIL  
 SYGNWGYVADPSNAKKTNILEDRAKETALTMDAAIIEFINTNLSLKDERTTGDTYEEIIKQSINVNDSS  
 TQEQTQNITNIIDKVNSKIKASASGKIRGIRTLKKWSYTSENGIEHVGAVRFYSYENLANTNEALNSKN  
 ATKNEAKKSSSIQRSSNNVNSMDDF

SEQ ID NO:2

ACE 5 Cj0005

>AnrP544820 (NC\_002163) putative molybdenum containing oxidoreductase [C.  
 MKQNDQKENRRDFLKNIGLGLFGISVLSNFSFENFLGSKALAKELPDFKIEGKKDLIYHGEKPLTAETEI  
 YALDSDFTPKPNENFFVRNNGLPPSLETIKERLHKGWTLEIDGESIINKSYTIEDLKKKFKYTYALTVEC  
 GGNRSEVIPSTKGTQWGYGAVACGRWTGVRKDILKDCGIKNDAVYIGYYGIDTKLNGEETSPISRGVP  
 ISKALQDETLLIAWAYEGKDIPLVNGYPLRLVCGGYPASTSGKWLKYKISVRNKHIDGEKMEGSYKVPVNPV  
 KPGDFNYKGEMKIIIESMPIRSVITNIKNGSEIKANKKFEVRGKAWAGELEVSEVYVSNDYGTWTKAKVE  
 KPLNRLAWQKWSAQISIPTKGYYEIWARAIDSQGNSQPMVLAQWNPGGYINNACHRVNVYGV

SEQ ID NO:3

ACE 29 Cj0029

>AnrP372217 (NC\_002163) cytoplasmic L-asparaginase [C. jejuni]  
 MKKAKSRIAILGTGGTIAGFIDSTIATTGYAAGAIDIDVLIKAVPQIRDLADISWEQIANIDSSNCDEI  
 WLRLAKKIAKLFAEGIDGVVITHGTDMEETAYFLNLTIKSDKPVVLVGAMRPSTAISADGPKNLYNAVA  
 LVVNKEAKNKGVMVAINDKILSARGVVKTHSLNVDAFSSPDFGDLGYIVDGKVFYNNVIKAHTKNAPFD  
 VSKLTSLPKVDILYSYSNDGSGVAAKALFEHGTKGIVVAGSGAGSIHKNQKDVLLKGLKVVVSSRV  
 VAGCVAVSDSDEKLGFIASDNLNPQKARVLLMLALTTSQPKKIQEYFLKY

SEQ ID NO:4

ACE 37 Cj0037

>AnrP501075 (NC\_002163) putative cytochrome c [C. jejuni]  
 MKKHILLGLCLSLSLSAKSVSDYKVGEELSKEVYFKELSKRKPVQEWPNKNL SINDVPKGKQGDLIR  
 YGIELLSKTESTLGPYSKLLKTSNEVNCISCHMDNDGNGLPGTKKVIPFLNLLNNYPRLDIETMKI1ISV  
 EDRIRGMGGTDSHRFNDSKEMKAILAYFKWLKEAYGIKDGVKLEGDFFAKMNFPNRPADEPVRGKKLFEE  
 NCVACHGERGLGVNDNQEQQSGHLYPSLLIYPDGGHMMAPFLARFLKSAMPFGASADNPILSDEDALD  
 IAAYVNTGFRVRMPITTENRAGLDTAYSQPKLPEYFASQPNLDPKEYIKVVKYGPWKNPNHFPGE

SEQ ID NO:5

ACE 84 Cj0093

>AnrP666574 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKIIKILFLGLFLSLNAKVTTTSTKSSTGEGTGLTREDAINNAIEAIGKMSGVSINSLKKSNNTSVS  
 TDNSGSNIQDNYSEQISKATKGRADTYEINSVEQDANGKYTANVTIFKTTTKKYQAPGLSADNRRSITV  
 FDSTPDAAKRGIGSALQQKIIISDLSQSRKFNVLDRDSSGYEMEKALIKSGDAASDEVYKLNMLATDYI  
 LLFSISGLEGQKTSNLTGKSKTEIEVIVDYRVLFFATRQIKFSNTLSMKVNLKDNLSANETALKQIAN  
 RIAGDILNAIYPLKVASVENNEVIFSQSLNQGDVYECFALGKVIKDTYTKENTGRVESKTGSIEITRTSP  
 KFSYAKITEGSVKVGDICRPLSNTGSGNGYTIGRDANYQTQEGGGVNLGF

SEQ ID NO:6

ACE 98 Cj0107

>AnrP732169 (NC\_002163) ATP synthase F1 sector beta subunit [C. jejuni]  
 MQGFISQVLGPVVDVFNDYLPOINEAIVVNFESESEGKKHKLVLEVA AHLGDNVRVTIAMDMDGLVRLK  
 AEALGAPISVPVGKVLGRIFNVGTGDLIDEGE EISFDKKWAIH RDPPAFEDQSTKSEIFETGIKVVDLLA  
 PYAKGGKVGLFGGAGVGKTVIIMELIHNVAFKHSGYSVFGAVGERTREGNDLYNEMKESNVLDKVALCYG  
 QMNEPPGARNRIALTGLTMAEYFRDEMGLDVLMFIDNIFRFSQSGSEMSALLGRIPS A VGYQPTLASEMG  
 KFQERITSTKKGSITSVQAVYVPADDLTDPA PATVFAHLDATTVLNRAIAEKGIYPAVDP LDSTS RMLDP  
 NIIGEEHYKVARGVQSVLQKYKDLQDIIIAILGMDELS EEDKLVVERARKIEKFLSQPFVAEVFTGSPGK  
 YISLEDTIAGFKGILEGKYDHL PENAFYMGVNIDEAIAKADKLKG

**FIG. 4****12/20**

SEQ ID NO:7

ACE 103 Cj0112

>AnrP511634 (NC\_002163) periplasmic protein [C. jejuni]  
 MKKIVAIFLVFLGSLWAEDPVIDVVNSGVLPKIIVKDNSLSDENLKKSFYNIIVNDLKVSNSFEEVAN  
 ATETSNYIFFEYTLNKNGNTLSLNVKIKAGGSDKSEQTYTLNGLEQYQPFALHKSVKASVNALGLAPVDWMD  
 HKILIAARNSSSSKKSQIIMADYTLTYQKVIVDGGNLNFPKWNKEQTLFYYTAYDHDKPTLYRYDLNTNA  
 SKILSSGGMVVASDVNVNDGSKLLVTMAPKDQPDVYLYDLNTKNLTQLTNYSIDVNGNFIGSDDSKVVFV  
 SDRLGYPNIFMQDLNSNSAEQVVFHGRNNSAVSTYKDFLVYSSREPQAGVFNIIYLMINSIDYIRQLTAN  
 GKNLFPRFSSDGGSIVFIKYLGQAQSALGVIRVNANKTFYFPLRVGKIQSIDW

SEQ ID NO:8

ACE 134 Cj0143

>AnrP57234 (NC\_002163) periplasmic solute binding protein for ABC  
 transport system [C. jejuni]  
 MKKIIILFILSLGIFYTFTQAKNLEQEQQNTSSNLVSVSIAPOAFFVKKIAANTLDVNVLPPNSNEHNFEF  
 KPSTMKKLEKSDIYFTIGLEFEKVFDTDKFKQNFPKLQVINMOKNIALIQTHDTHEHSHEHHHEHGFDP  
 HTWLDPLVQTMALNIYDTLIQKYPQNENLYKENLDKFLAELDSLNLQIAASKLEKLKNREFVVYHPSWTY  
 FAKRYNLTQIPVEILGKEPKSKDLQKLITLMKDKNLKVIFVQNGFPENAAKTLAKECDAKIYKIDHLSYD  
 WENELLKTADAFSHNL

SEQ ID NO:9

ACE 159 Cj0169

>AnrP829849 (NC\_002163) superoxide dismutase (Fe) [C. jejuni]  
 MFELRKLPLYDTNAFGDFLSAETFSYHHGKHHNTYVTNLNNLIKDTEFAGKDLVSIIKTSNGGVFNAAQV  
 YNHDFYFDCIKPSTGCGCGGSCQSIDANLQAALEKEFGSLENFKAEFIKGATGVFGSGFWLVYNTKNQK  
 LEFGVGTNSAATPITEDKVPLLVVDVWEHAYYDHRNARPAYLEKFYAHINWEFVAKAYEWALKEGMGSVS  
 FYANELHPVK

SEQ ID NO:10

ACE 183 Cj0193c

>AnrP139712 (NC\_002163) trigger factor (peptidyl-prolyl cis /trans  
 isomerase, chaperone) [C. jejuni]  
 MEVKAKQLDSVNATASVKIPSGMIKSEVENLAKKASKSVKMDGFRPGKVPVSAVLKRYERELTQDAEQL  
 FKSAVNSALQELKKENKELVGEPYFEKFDRKDGEIIAELILSFKPEIKLEGYELIPEYQTPKVKSKKEID  
 EKKDELLKRFAPEAIKTKRALKEGDFAKDFEGFVDDKAFEGGKAENYVLEIGSKQFIPGFEDGMVGMK  
 IGEEEKDIKVTFPKEYGAHLAGKDAVFVKVHLHEIQELKIPELDDEMLKKLLPGEEKASVELDEKLKEQI  
 KNEKLFKLVNDDELKGKFADALIEKYNFDLPLKGIVEQETDMQMRAAFNTFSEKEIEELKASKEKYQEKRDS  
 FKEEAQKSVKLTFIIDELAKLRKIEVNDQELIQAIYFEAYRYGMNPKEHLENYKKQGALPAVKMALIEEK  
 LFNDIFIPKTEKSEKVKKEKEDK

SEQ ID NO:11

ACE 259 Cj0285c

>AnrP467527 (NC\_002163) chemotaxis protein [C. jejuni]  
 MFDENIVKTGSNEMELVDFRIFKQGHDKVYEGIYGVNVSKVREIIKIPSLTELPGVPDYIEGIFDLRGVV  
 IPVVLAKWMQITEPESTMLKPRVIITEFSNILIGFIVHEAKRIRRINWKDIEPATFSTGSGALDKGKIT  
 GVTRIENDELLILDESVDLGIYAPKTDIDFGKIEKFTGTLILDDSMTARKRVKEMMQQMGFQVVE  
 AKDGVEGINKLEELSQIYGESLNDTLKIIIVSDVEMPPMDGFHFAARIKEDPRFKDIPIVFNSSLNEFMN  
 EKGVQEAGGEGYLVKFNASDFFNEIAKVIKKHQSEQG

SEQ ID NO:12

ACE 332 Cj0358

>AnrP681041 (NC\_002163) putative cytochrome C551 peroxidase [C. jejuni]  
 MKVKSLLIASLVAFSSLNAASLIDEAKNSGLVALPKDQKGVDIEILKQNGVKASEFTLEKAELGKKLYFEP  
 RLSKSGIISCNCTCHNVGLGGTDGISTAIGHKWTANPHLNNSPTVYNAVLNNNTQFWDGRAGTLADQAKGPI  
 QADPEMATPAKLAVAKEKSSLPEYVSEFKKIGKSGVNFNDNIADAIAFERTLITPSRFDKFLEGDEKALT  
 KEEQKGLKLFIDKGCVACHNGVNLLGGNMQAFEVAGKYKFANLGDFKGDANGMVKTPTLRNVAETAPYFHN  
 GAIWNLKDAIKEMGSVQLGIKISDKEAKSIEFLKSLTGTKPAIVYQPLPISTEKTPKPEL

SEQ ID NO:13

ACE 419 Cj0448c

>AnrP569688 (NC\_002163) putative MCP-type signal transduction protein  
 [C. jejuni]

MFGSKINHSDLQKLEEEENKNLTHKIEKFQSENLELKKNITSLEQALESKLKDLLNVLLTGVLKNTII  
 QGDMLENVNKAEVISYSKTSLAEDELNHIANSINASLGNITESANKTRDVAGTLHRSVDEITNVINLI  
 KDVSQDTNLLALNAAIEAARAGEHGRGFVVVADEVRKLAETQKATTEVEMNINLLKQANEMYTQSEQV  
 EKISIDSNNAHIMSFSEKFTHLVNEAHSTNSAVGIASEAFVSLAKLDHIAFKLNGYKEIFSKSGKQLADH  
 TSCRIGKWLASTGKERFGQNKSLKINEPHEKVHENMNNAITIANTEDISKDITQHSIINKCEVAENASL

**FIG. 4****13/20**

DLFNVFKEMLDESDH

SEQ ID NO:14

ACE 420 Cj0449c

>AnrP852550 (NC\_002163) hypothetical protein Cj0449c [C. jejuni]  
MLHEYRELMSELKGKDAHFDKLFDRLHNEELDDMIKDAEEGRTSSLSSMEISTLKKEKLHVVKDELSQLANYK  
K

SEQ ID NO:15

ACE 481 Cj0511

>AnrP255677 (NC\_002163) putative secreted protease [C. jejuni]  
MMELILKTKRFFAGLAGFATTFILCLFLTSHLQAKVDQKEEQVQKRLEALDKLTKTTLAIVEQYYVDDQNI  
SDLVDKSLSGLLSNLDAHSSFLNEKDFNDMKIQTNGEFGGLGITVGMKDGAUTVVSPIEGTPADKAGIKS  
GDIILKINDEATLGINLNDAVDKMRGKPKTQITLTIFRKGATKPFDVTLTREIIKIESVYAKMIENENIL  
YLRVTNFDKNVVDVASKELKKYPNVKGVIDLRLNNPGGLLNQAIGLVLNLFVDKGVIVSOKGRIASENQEY  
KADPKNKISNASLVLVNVNGGSASASEIVSGALQDLKRGVIVGENTFGKGSVQQIIPINKTEALRLTIARY  
YLPSPGRTIQAVGVKPDIEVFPGVNTQEDGFSIKESDLKQHLESELEKIDKNKKEDKQENKDNKNLISQK  
QINDDAQLKSAIDTIKILNIKQGQ

SEQ ID NO:16

ACE 528 Cj0559

>AnrP252410 (NC\_002163) oxidoreductase [C. jejuni]  
MKKIDLIVVGAGPTGIGCAVEAKLKNKEVLILEKSNNICQTLMQFYKDGKRVDKAYKGCEGTNHGHVPFE  
DGTKESTIETFQNALKHEHNIEVEFGSEVESVKNENGFLVSTAKGVYECKNIIVAIGRMGKPNKPDYKLP  
MTLTKIINFNANSVLGNEKILVVGGGNSAAEYAVDLANSNOVSLCYRKKEFTRLNDINLKDIEAGNSGK  
VELKLGIDINEVEDDNGKAKVNFTDGTSDIYDRIIYAIGGSTPLDFLQKCGINVDDKGVPMLDENKQSNV  
KGIFVAGDIATKNGASIVTGLNDAVKILSVL

SEQ ID NO:17

ACE 582 Cj0613

>AnrP916533 (NC\_002163) possible periplasmic phosphate binding protein  
[C. jejuni]  
MKKILSLSVTSLALCGALNAVDLKIAGSSTVYPFTSFVAEYASIKNTKTPIVESLGTGGGFKVFCEGTT  
DISNASRPMKLSEFETCKKAGVTDIVGMMIGYDGIVLAQNKTNAPlNITKKEFLALAKEIPQNGKLIPN  
PYTNWNQINKNLPNRKISVYGPSSSGTRDTIEELVMSDVSKKIPEYKGEYKTIQDGAYIPSGENDNL  
VSKLTIDKDAFGIFGYSFLVSNSDKINAANIDGVTPSEESIADEKYLARSLFIYINAKKNPKEAFDFAK  
IYMSDDLAKSGGELEKIGLVLPLSDDKLKASQKHVEDRKILNDELVKAGKVF

SEQ ID NO:18

ACE 605 Cj0636

>AnrP126795 (NC\_002163) NOL1\NOP2\sun family protein [C. jejuni]  
MQNILSSFAQEKNVCVFANTLKTSEELEKEFLKQNLKFKKINVYCYLFDAKDKAIlSSMKAfNEAHFYI  
QNYSSYLCALNLEVKAQSVLDCAAPGGKSiNLANFMQNTGYLACNEMSRDRFFILQKNLKNYGVNAKV  
FMKDGNIGNLCPPLKFDKILLDAPCSTFAKIGFDLEKSYKEIKNIAKTQKKLLHSALKALKIGGELVYST  
CTFTKEENEVEENALKSEFKLELLDIDLENVEAKAGQSEEFAEISKCRRIPLSLDYDGFFIAKLRKLC

SEQ ID NO:19

ACE 667 Cj0706

>AnrP327756 (NC\_002163) hypothetical protein Cj0706 [C. jejuni]  
MNKYLEQLVLLSKIDQEIDSYEPKIDSINKTLKDAELKIEKINADLEKIDEEIKDIENQKIQNNAHISEF  
SAKIKDLSSKSGVVKTEKEANALKIEEDIKEQLDAANDEIVRLDKILENKETYKKELEEEKIKQEQQNIN  
EIRVSIKSEMEVLEKDRMSVYDKKTKLVSEMNQKVLSFYEKIRKWAkNTAVVPVKKQACYGCFMkIYDkT  
YLSVVKGEEIVTCPHCGRILYKEQEEQN

SEQ ID NO:20

ACE 676 Cj0715

>AnrP684299 (NC\_002163) transthyretin-like periplasmic protein  
[C. jejuni]MFSIKKTLLILASVPMFLSATEYQLSTHVLDITSGQPAPKVKVELYKLEANQQWKKVSEEFTEENGRIGD  
LLPYEKAENRAFGIYKLKFFTQDYYTSHKINTFYPFVEVSFELSKDQKHYHVPITLSPFGYSTYRGS

SEQ ID NO:21

ACE 731 Cj0779

>AnrP191193 (NC\_002163) probable thiol peroxidase [C. jejuni]  
MSIVNFKGKGNPVKLKGNSVEVGADAPKVNLKAKDLSVIEIGAAGKTQIILSVPSDLTPVCATEAREFNKKV  
ASYNGAEVIVVSMDFPFAMGRFCSTEGIENLSVASDFVAKEFGEKYGVLINEGALEGLLARAVFVIKEGK  
VAYKELVNEITEMPDIAKLDAFFGGSSCCGGCGCH

FIG. 4

14/20

SEQ ID NO:22

ACE 853 Cj0909

>AnrP318705 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKILLLGALFAVNLWAVNDIEVKNAFVKQTTPHAQNSAIFLTIFNNNTKDIALISAKSDISEVSELHTH  
 IHKDGGKMMMQKIPETIIKAHSSTELKSGGYHIMLLKLKKPIIKDTKVNLDLKFNNHKTIELKNIDSKEF

SEQ ID NO:23

ACE 937 Cj0994c

>AnrP493933 (NC\_002163) ornithine carbamoyltransferase [C. jejuni]  
 MKHFLTLRDFSKEEILSLVNHASELKKEPKKLLQDKTLAMIFEKNSTRTRMAFELAITELGKALFILSSN  
 DLQLSRGEPVKDTARVIGAMDFVMMRVNKHETLLEFARYSKAPVINALSELYHPTQVLGDLFTIKEWNK  
 MQNGIAKVAFIGDSNNMCNSWLITAAILGFEISIAMPNYKISPEIWEFAMQALISGAKISLGYDKFEA  
 LKDKDVVITDTWVSMGEENEKERKIKEFEGFMIDEKAMSANKDAILLHCLPAYRGYEVSEEIFEKHADV  
 IFEEARNRLYVVKALLCFLDNQRGRE

SEQ ID NO:24

ACE 941 Cj0998c

>AnrP979073 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKILVSVLSSCLLASALSAVSFKEDSLKISFEGYKTKDMIGTKGEFKNVEYKFSKNIKDLASYLKGAKA  
 TIKPSNAFMGEGNNDITNNITKVFFPALLGDTDIKVFQDVIAGENKGVISAKITMDKKSTIVPLTYTIK  
 DNKFEAKGQQLDLHTFKNGSKALKALSDVAAGHGGISWPLVDISFNADLAE

SEQ ID NO:25

ACE 961 Cj1018c

>AnrP257863 (NC\_002163) branched-chain amino-acid ABC transport system periplasmic binding protein [C. jejuni]  
 MKKSLILASILSLSAAEVKIGVVLPLSGATAAYGQSALEGIKLANSMQSALSNGDKVSLAIIDTKGDK  
 LESSSGANRLVSQDKVIGLIGEMVTANTLQVMRVAEDNKIPLIAPAATGDRLLDKKIYSSRVCFMDSFQG  
 SSLAKYVFSKLNLYKSAVIVVDQSTDYSLGLIAKAFEKQYKSNGGQILRILRVNSGDKDFRAIVAQVKSLNP  
 EFIFLPLYYSEASLFARQSKLAGLNIPMGSADGVADQTFISLAGDASEGYIFTDSFDANNPTTKLSKEFI  
 SVYEKAKGTKEVPNFSAMGADAYFVMLNAMNACVENLTSKCVNEKIHQTKNYQGVSGVISIDQTNATRS  
 VVVKEIKNQKQNYKDIINP

SEQ ID NO:26

ACE 962 Cj1019c

>AnrP326257 (NC\_002163) branched-chain amino-acid ABC transport system periplasmic binding protein [C. jejuni]  
 MKKLTTLTSVLTMVNCYAKDINIGVVPLTGTVAAYGQDFVNGIELANKLQPKLSNGDVIKLITIDTKG  
 DKLETSNGVNRILATDKVLGIIGEATTPTNTQAIISIAEKKIPLIAPVASGDKLLDKKKYASRVCFKDSF  
 QGDKFATYVSKDLGLKNAVIIIDQSNVYSLGLARAFENSFKNNNGGIIKKLVINSQDKDFRAVVSQKL  
 NPDFVYMPIYHPEALIARQARQIGFDKLLVAGDGVNNQTFIDLGGSAVNGVIFTDSFDYNSPSTQLGKD  
 FVAAYEKVKGTKELPAFSAMGADAYFVMLNAMNACVDNLSSECINSKIHQTKDFQAVGGVISIDESGNAI  
 RSVVIKEIQNQKQNYKTIINP

SEQ ID NO:27

ACE 984 Cj1041c

>AnrP198268 (NC\_002163) putative periplasmic ATP/GTP-binding protein [C. jejuni]

MKKYVLSLALLGSLLGASELKYQEFDGFKSPESIFVDKNYVYVSVNGEKLPLAKDNDGFISKLDKNGKV  
 LEYKFLTHLNAPKGMEIGKTLVYVVDIDVLRGFDLKTKEIFNLPIKGAIFLNDIEKLDDNTLLVSDTGT  
 GLILKVDLKTQYDELLKLDLAKFGFPNGLYLDRKKHKLFIAGYHPDGVSQGGVVMAYDLNTKELSIIKNE  
 KESYDGIVPYKDGLLVSSWGNNLNGIYIYNLDNVKSVKLELPLMKGPADIFIEGNILWIPKMVEGKIFKVE  
 LNK

SEQ ID NO:28

ACE 1094 Cj1153

>AnrP385049 (NC\_002163) putative periplasmic cytochrome C [C. jejuni]  
 MKKLLVVSALACLGVSFAADGATLFKKCAVCHGANADKVYLNKPALKTLSSAERLQYMKEYSEGKRNA  
 YGQGAIMKLNKGLTEEDFKIAEHIETLK

SEQ ID NO:29

ACE 1155 Cj1214c

>AnrP470247 (NC\_002163) hypothetical protein Cj1214c [C. jejuni]  
 MFKTIIVCFALNLSLFAVGFDLPIKSELVKVDDIYGYIKDSDDIKLYSSGVVVQHFSNSQSTIARASVI  
 DKKNGLAKLEFSVFSALKQDALPLPNVLPKVGDEVVLNFLYDRGLVIAFDEQTYNELVREFPQIYFTHID  
 IFGAQLIRATLSPKRSDFRQFCDDNAVGLVVALENHAEVVDCQDFNKLYEVPIKPTSVQVFFYSRIG  
 GYKSNFFDFNSQEIGNYYRYYDALINLPKVQ

**FIG. 4****15/20**

SEQ ID NO:30

ACE 1227 Cj1287c

>AnrP530915 (NC\_002163) malate oxidoreductase [C. jejuni]  
 MNLKEEALKYHGGKIDIVPSKPMATSYDLSLAYS PGVAEPCLEIAKDNELAYTYTNKANLVAIVSDGSA  
 VLGLGNIGAQASKPVMEGKACLFKKFANVNAYDIEINVHSIEEIVNFCKALAPTVGGINLEDIAAPKCFE  
 IEAALQDLGIPVMHDDQHGTAIISTAGLMNAMEISGKKFKDIKVVGAGAAGIASAKMYRNLGVENIIL  
 VDSKGVIISKDRNDLTPQKLEFAVDSKEKTLKEVLKGADVFLGLSAPKILDDEMVL SMAKDPVIFALANPI  
 PEVMPEDVARLRKDAIVGTGRSDYPNQINVNLGFPIFRGALDVRASKITENMKVAAAKALADLAKLPVS  
 DAVKKAYNLSTLEFGRDYVIPKPFDERVKAAVSTAVAAA VKGVA KVNFDEKAYFESLK

SEQ ID NO:31

ACE 1320 Cj1380

>AnrP108083 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKLSLILVCSASLFAASNSEISDFYSKSIKAQFPNATVS VSNRQKVGVNTGFESVIVSVELNGQKQENIL  
 FTKDSLITPDLIDLKTG ISYAQEYEMKKFQEARENFTKNAKAVAQKETMVIALGDKNKP AIVFSDPECP  
 YCREHLAQIDDELKNYQVNYI LTPVHGKSAFEKSALIYKEAKKAKNDKEKIAILNKYYDANIKNYPKVSD  
 AELKEVFSLYEKYRSLGSATPTI IK

SEQ ID NO:32

ACE 1431 Cj1496c

>AnrP947055 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MIKKFILLVFISSVVFGAEQDC EQYFEAR KAQIELQTRFDEARQSLEAYKASFEALQKERLENLEKKEA  
 EVNATLAKIEELKLENARLVEEQQQKILNSINDKTQGRVKEIYSQMKDAAIADVLSQMDAEDASKIMLSLE  
 SRKISGVLSKMDPKKASELTLLLKNLDNNASN

SEQ ID NO:33

ACE 1449 Cj1516

>AnrP407504 (NC\_002163) putative periplasmic oxidoreductase [C. jejuni]  
 MNRRRNFLKFNALT LASMGVAYANPMHDHMHSMHKNHSINHLDTSFINFAPKNLKLLDPKQFPQGEILKAL  
 PLLKNESKEKNIFRATLEI KENHIELIKGKKTLYT YGLVPA PKIEVFEGDKLEILVKKNKLKEATTIHW  
 HGVPVPPDQDGSPHDPI LAGEERIYRFEI PQDSAGTYWYHPHPHY TASKQVFMGLAGAFVIKAKKDALSH  
 LKEKDLMISDLRLDNEQI P QNNNLNDWLNGREGEFV LQFKPKIKLATNERIRIY NATAARYLNLRIQ  
 GAKFILVGT DGG LIEKAIYKEELFLSPASRVEV LIDAPKDGNFKLESAYYDRDKMMVKEE SNTLFLANIN  
 LKKEKLELPKNLKIFKPLEEPKEFKEIIMS EDHMQHGMGKSENELKIALASMF LINGKSYDLKRIDL S  
 SKLGVVEDWIVINKSHMDHPFHIHGTQFELISSKLNQVKA EFRAFRDTINVRPNEELRLKMKQDFKGL  
 RMYHCHILEHEDLGMMGNLEVKE

SEQ ID NO:34

ACE 1469 Cj1540

>AnrP818860 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKIISLALALASAAAELK MATTSTDNTGLLDALKPLYEKE SGN TLK WVA GTGAALKMGEDCNADV  
 LFVHSPKAEKEFMKKGFGVDRTPV MYNDFIIIA DKS LASKFKGK NLKESLELIKNEKLT FISRGDKSGTD  
 NKEKSLWKNLGGVPEKQSWYQQSGQGMLASIKIAEEKKGVIL TDRGTYIKYEANEK GKP NLVIVNEGDD S  
 LKNFYSVIATNPKHCKNVN YTEASKF I KWV TS DKT LNFIADFKL LNKPLF VIDAKTRKD

SEQ ID NO:35

ACE 1584 Cj1659

>AnrP294550 (NC\_002163) periplasmic protein p19 [C. jejuni]  
 MIKKVLSVAAA VISTNL FAGEVPIGDPKELNGM EIAAVYLQPIEMEPRGIDLAASLADIHLEADIHAL  
 KNNPNGFPEGFWMPYLTIAYELKNTDTGAIKRGTLMPM VADDGPHYGANIAMEKDKGGFGVGN YELTFY  
 ISNPEKQGFGRHVDETGVGKWFEPFKVDYKFKYTGT P K

SEQ ID NO:36

ACE 1569 Cj1643

>AnrP407676 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKILII CMLFTLSFGIERPKFEDFLAGYERNKASMLN YEGMPA FALSENLLAVLKQPN AKL NKVVKYDP  
 FLNLYLVRTDFSLIPTPMGDEEK LTRNDWVG IWD PNKP YIGHIKYLAQNIDEK DQLDFNSKIGLLGTPCC  
 EMMG IALNNSSF I GNR YLKHFMK YNDVYWG D IGVDFV VREN KIYVNN VRKNPQFLINDQV I SVDGLP AND  
 LRKLNEKILFADRGSTLYFQVLRDNMDLNISTEVFAKDL SKFNL PDSKPKPKITNFTS NLGLTVNASL VV  
 TKIDPKSKVSNAGFMVGDKILRVNNIILNNFKELQNL SAGNDF S I LIERKSTKLPLS FN FNNELGGNANS  
 GGDGKFQFFIRLTK

SEQ ID NO:37

ACE 96 Cj0105

>AnrP758295 (NC\_002163) ATP synthase F1 sector alpha subunit [C. jejuni]  
 MKFKADEI SSI KERIENFDLNLEIEETGKIIISVADGVAKVYGLKNIMAGEMVEFENGDKGMALNLEESS  
 V GIVILGKGEGLKE GASV KRLKKL KV PVGEALIGRVV NALGEPI DAKGVINANEYRFVEEKAKGIMARK

FIG. 4

16/20

SVHEPLHTGIKAIDALVPIGRGQRELIIGDRQTGKTTAVDTIISQRGQGVICIYVAIGQKQSTVAQVVK  
 RLEEHGAMEYTIVVNAGASDPAALQYALAPYTMGEFFRDNAKHIALIVDDLSKHAVAYREMSLILRRP  
 PGREAYPGDVFYLHSRLLERASKLNDLGAQSLTALPIIETQAGDVSAYIPTNVISITDGQIFLETDLFN  
 SGIRPAINVGLSVSRVGGAAQIKATKVSGTLRLDQAQFASDLDEASRKQLERGQRMVELL  
 KQPPYSPSVEKQVVLIFAGTKGFLDDIAVSRIKEFEDGIYPFIEAKHPDIFEQIRSKKALDSLEEKLA  
 KAINEFKANHL

SEQ ID NO:38

ACE 165 Cj0175

>AnrP550554 (NC\_002163) putative iron-uptake ABC transport system  
 periplasmic iron  
 MKKIFFMFLTAVSFLGASELNIYSARHYNADFEIKKFEKTGIVNHTQAKASELIKRLSLEGSNSPAD  
 IFITADISNLTEAKNLGLSPVSSKYLEEPIPAHLDKDEWFAITKRARIAYNKNTNIDISKMKNYED  
 LAKAEFKGEIVMRSATAPYSKTLLASIILANDGNKEAKAWGVLENLATNPKGGRDQARQVFAGEAKFA  
 VMNTYYIGLLKNSKNPKDVEGNSLGIIFPNQDNRGTHINISGIAIMTSSKNQDAAKKFMEFMLSPEIQQ  
 ILTDSNYEFPIRNDVELSQTVKDFGTKEQDQIPVSKIAENIKEAVKIYDEVGVF

SEQ ID NO:39

ACE 257 Cj0283c

>AnrP602342 (NC\_002163) chemotaxis protein [C. jejuni]  
 MSNEKLEQILQKQQTQMAGPDVDQREDDIIQLVGFVVGDEEYAIPILNQEIJKPIEYTRVPSVPDVVLG  
 VFNMGRGNVMPPLIDLAQRFHLSKMTPQTRYIVLRGETNGTGVGGNAGFVIDRLTEAIKIHRNRIDPPPE  
 TLVKDKGMIYGIGKRDENILTILKVEALLKREF

SEQ ID NO:40

ACE 277 Cj0303c

>AnrP311344 (NC\_002163) putative molybdate-binding lipoprotein  
 [C. jejuni]  
 MKKFVVFVFGILLFVSCLNAAQNLISIFVASSASKAMSEVKDEFLKTHPEDKIELVFGASGKYYELLKQGREF  
 DLFFSADTKYAKAIYDDKNALIKPKVYVLGVLALYSLDENLLQGGVENLKEKANKITHLSIANPKVAPYG  
 VAAKEVLENLGLNELLKDKIVLGENISVPVLHVDSKNSDIAVAYSLVSSINHPKGAVIIDAKYFSPLE  
 QSYVITKYAKDKKLAFEFNEFIGSSKAKEIFKKYGFSTP

SEQ ID NO:41

ACE 308 Cj0334

>AnrP505685 (NC\_002163) alkyl hydroperoxide reductase [C. jejuni]  
 MIVTKKALDFTAPAVLGNNIEVQDFNLYKNIGPKGAVVFFPKDFTFVCPSEIIAFDKRYQEFKNRGIEV  
 IGIISGDNEFSHFAWKNTPVNQGGIGQVKFPLVADLTQIARNFDVLYAEAVALRGSFLLDADGTVRHAVV  
 NDPLGRNIDEMLRMVDTMLFTNEHGEVCPAGWNKGDEGMKANPKVVAEYLGKNEAKL

SEQ ID NO:42

ACE 388 Cj0415

>AnrP72219 (NC\_002163) putative oxidoreductase subunit [C. jejuni]  
 MAEVLKKVDDVVTVGAGWTGGIVAAELTKAGLNVLSLERGHMQSTENFNYIHDEWRYGINYGLMQDCSKDT  
 VTFRHDPGSLALPYRKMGFSLLGNNVGGAGVHWNGWTFRFPYDFEIQTLQSKQRYGNKLGNDYTLQDWGV  
 TYKDMEEPYYDRFEKTCGVSGEPNPLAEKMGAFRSPSPQPEPLENTKMLKRFEAAKSSNLHTYRLPASNS  
 KGGYTNPDGQDLAPCQYCAYCERFGCEYAKASPLNTVIPKAMSTGKYTIRTYNSVTQILKKDGKVGVK  
 FVDTRTMKEYIQPADIVVLTSYMNNAKLMLVSNIGEIQYDPKTGKTLGRNYCYQMNMGTTAFFDEQFNT  
 FMGSGALGTTISDDFMNDNFHDHSKEKFLHGAMIYSVQLGTRPIQSAPLPGAPTWGAFFKKALNFTRAI  
 TVGGQGASLPHKNNYLSLDPTYKDAFGMPLRLTYNFTDQDRALHKFITDKTAEVAKRMQGVSIKKGAY  
 LKDYSVVPYQSTHNTGGTTMGADRETSVNVNTYQHWDADNLFVVGAGNFQHNSGYNPTDTVGALAYRCAE  
 GILKYHKSGKSLA

SEQ ID NO:43

ACE 393 Cj0420

>AnrP490750 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKKVLLSSLVAVSSLSTGLFAKEYTLDKAHTDVGFKIKHLQISNVKGNFKDYSAVIDFDPASAEFKKLDX<sub>1</sub>  
 TIKIASVNTENQTRDNHLQQDDFFKAKKYPDMTFTMVKYEKIDNEKGKMTGTLTIAGVSKDIVLDX<sub>2</sub>EIGG  
 VAKGKDGKEKIGFSLNGKIKRSDFKFAX<sub>3</sub>STSTITLSDDINLNIEVEANEK

wherein X<sub>1</sub> is V or A, and X<sub>2</sub> is A or T, and X<sub>3</sub> is T or A

SEQ ID NO:44

ACE 711 Cj0759

>AnrP586832 (NC\_002163) heat shock protein dnaK [C. jejuni]  
 MSKVIGIDLGTNTSCVAVYERGESKVIPNKEGKNTTPSVVAFTDKGEVLVGDASKRQAVTNPEKTIYSIK  
 RIMGLMINEDAACEAKNRLPYHITERNGACAAIEIAGKITYTPQEISAKVLMKLKEDAEAFLGESVTDavit

FIG. 4

17/20

VPAYFNDAQRKATKEAGTIAGLNVLRINNEPTSAALAYGLDKKDSEKIVVYDLGGGTFDVTVLETGDNVV  
 EVLATGNGNAFLGGDFDNKLIDFLANEFKDETGIDLKNDVMAQLKEAAENAKKELSSANETEINLPFI  
 TADASGPKHLVKKLTRAKFEGMIDSLSVAETITKINBVSAGLKDEIKEIVM/GGSTRVPLVQEEVKFA  
 FNKDLNKSVPDDEVAIGAAIQGAVIKGDVKDVLSSLDVTPLSLGIETLGGVMTKIIIEKGTIPTKKHQVF  
 STAEDNQSAVTINVLQGEREFSRDNKSLSGNFNLEGIIPPAPRGMPQIEVTFDIDANGILTVSAKDKATGKA  
 QEIKITGSSGLSEEINNMVKDAELHKEEDKKRKEAVDARNAADSLAHQVEKSLSELGEKVAADKENIQ  
 KALDDLRETLKNQNASKEEIESKMKALSEVSHKLAENMYKKDEPNTANDKKKKDDDVDAEVE

SEQ ID NO:45

ACE 723 Cj0771c

>AnrP524051 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MNLFKIIILACILNLSSLFAQNITIGATPNPGSLLHELMKDDFKNKGYELKIVEFSDYILPNRALEEKEL  
 DANLYQHCKPFLEEEYNLKKGSNLIAATTPLVLIAPVGVYSKKIKNLLENLKEGARVAIPNDATNESRALELEK  
 AKLIELNKNTLKTPLDINKNPKKLKFIELKAAQLPRLADDVDIAIINSFALGAGLNPSKDTIFREDKNS  
 PYVNYVVVRSEGNSEKTKVIDEILRSDKFKATINEHYKDILIPAF

SEQ ID NO:46

ACE 724 Cj0772c

>AnrP579672 (NC\_002163) putative periplasmic protein [C. jejuni]  
 MKIKSLFIASILTLSLNANALETITVAATPVPHAEILEQVKPDLEKQGYKLEIKEFTDYVLPNLAVDNGE  
 ADANFFQHPTPYLEEFNKNKGTKLIKVAIAIIEPMAVYSKKYKSLDDIKEGVKIAIPNDPTNESRALDIIA  
 KKGLVLFKDKALKTPLDIIDNPKKIKFVELKPAQLPRLNDVDFAVINSNYALSANLNPADSVFIEDKE  
 SPYANILVVVRVGHENDPKIKALIQALQSDKIKQFIIIEKYNGSVLPWF

SEQ ID NO:47

ACE 819 Cj0872

>AnrP694298 (NC\_002163) putative protein disulphide isomerase  
 [C. jejuni]  
 MRNFFCKFVLALVFYSSFALANNSFITLNPSLPSSSENSVIEAFSYKCIHCYNHHKFGTLEKLREAFPNLH  
 FKLYPVSLMNGEFSKEMNELFTFAQYKDEQNGKDASYSDSLSHKLADVYFVSYFLNKQRNFSNLDEFYDI  
 GLKAMNVNKNEVLFNLNTPKAKEILSEFQRANDIAKTYGTPAFVUNNGKYQINPSAINSMDLEDLVKKLS  
 NMK

SEQ ID NO:48

ACE 1060 Cj1118c

>AnrP515430 (NC\_002163) chemotaxis regulatory protein [C. jejuni]  
 MKLLVVDDSSTMRIIKNTLTRLGHDDVLEAEHGVEADLLTKNEDVKVLITDWNMPEMNGLELVKKVRA  
 EKKYEDMPIIMVTTEGGKAEVITALKAGVNNYIVKPFPTQVLKEKLEDVLGTSGEGAAE

SEQ ID NO:49

ACE 1169 Cj1228c

>AnrP679791 (NC\_002163) serine protease (protease DO) [C. jejuni]  
 MKKIFLSLSSLASALFAASINFNESTATANRVNPAGNAVLSYHDSIKDAKKSVVNISTSKITTRANRPSP  
 LDDFFNDPYFKQFFDFDSQRKGKNDKEVSSLGSGVIISKDGYIVTNNHHVVDADTITVNLPGSDIEYK  
 AKLIGKDPKTDLAVIKIEANNLSAITFTNSDDLMEGDVFVFLGNPGVGFSVTSGIISALNKDNTIGLMNQY  
 ENFIQTDASINPGNSGGALVDSRGYLVGINSAILSRRGGNNNGIGFAIPSNSMVKDIAKKLIIEKGKIDRGFL  
 GVTILALQGDTKKAYKNOEGALITDVQKGSSADEAGLKGDLVTKVNDKVIKSPIDLKNYIGTLEIGQKI  
 SLSYERDGENQASFILKGKEENPKGVQSDLIDGLSLRNLDPLRKDRQLQIPKDVLNGVLVDSVKEKSKGKN  
 SGFQEGDIIIGVGQSEIKNLKDLQALKQVNKEFTKVVWYRNGFATLLVLK

SEQ ID NO:50

ACE 1510 Cj1584c

>AnrP355324 (NC\_002163) putative peptide ABC-transport system  
 periplasmic peptide- [C. jejuni]  
 MLRWFVLLFLNLEAKIPKDTLIIAVENEIARINPAYSEDHDAVINLVFSGLTFDENMSLKPDLAKS  
 WDISKDGLVYDIFLRRDVWLHDGVKFSADDVKSIEAFKNPKNNSSIYVNPFEDIKSVEILNPSHVKITLF  
 KPYPAFLDALSIGMLPKHLENENLNTSSFNQNPIGTGPYKFVWKWKGHEYVEFKANEHFYLDKVKTPRLI  
 IKHIFDPSIASAELKNGKIDAALIDVSSLNPKNDENFGILREKSADYRALMFNL,DNEFLKDLKVRQALN  
 YAVDKESIVKNLLHDYAFVANHPLERSWANSKNFKIYKDPKKAEDLLVSAGFKKNKDGNFEKDGKILEF  
 EIWAMSNDPLRVSLAGILQSEFRKIGVVSKKVAKPAGSFDFYKVDLSFLIGWGSPLDPDFHTFRVFESSQD  
 SALNDEGWNFGHYHDKKVDIALQKARNTSNLEERKKYKDFIDALYENPPFIFLAYLDFALVYNKDLKGI  
 KTRTLGHGGVGFWTNVYEWSK

SEQ ID NO:51

ACE 1543 Cj1617

>AnrP111949 (NC\_002163) putative haemin uptake system periplasmic  
 haemin-binding protein [C. jejuni]

FIG. 4

18/20

MKKILIIIMSLFLIALNAKERLVVLDPASIELTFLMLKAEDQIVGIATLQHSNIYPKDKQTSKLTSGTFSNP  
 SLEKIVALKPSLVILSSYSLNLEEGLKNFGIKSINLKAERLEDITKNITTLGQITKKEKEAELLKQEFNQ  
 KFKKLSDKPLNKSATYLYSSNPLMAFNDSLIAIDLRLIGIKNLSPSQISRPVISAELYILKQNPDLIL  
 GINAKNNLLDTNALLKNTKAVKTGSIYFNKDTPIILLRSPKIIDRIQEFKTKLENNNF

Fragments of AnrP630851 (Cj0092)

SEQ ID NO: 52: TQQDINTQNEMSDASTKDITPKSIEDFFEEFAD  
 SEQ ID NO: 53: GITKDGKTFYTGKSTVAVNNDTDPQF  
 SEQ ID NO: 54: RIATSKIQNYEADNSTNAKEFDELPGDKVDQILNK  
 SEQ ID NO: 55: QLDKALKDGLIDTNLSLEDRKKTLLQEFLNKTMTN  
 SEQ ID NO: 56: TIVTQRGEYDVGVVAVISNKTQLAKD  
 SEQ ID NO: 57: AISEYLPKDTKGFLNEYGIRLVYDEN  
 SEQ ID NO: 58: DPSNAKKTNILEDRAKET  
 SEQ ID NO: 59: LSLKDERTTGDTYEEII  
 SEQ ID NO: 60: VNDSSSTQEQTQNITN  
 SEQ ID NO: 61: TLKKWSYTSENG  
 SEQ ID NO: 62: YSYENLANTNEALNSKSNATKNEAKKSSSIQRS

Fragments of AnrP57234 (Cj0143c)

SEQ ID NO: 63: IFYTFTQAKNLEQEQQNTSSNLVSVS  
 SEQ ID NO: 64: LPPNSNEHNFEFKPSTMKKLEKSIDIYF  
 SEQ ID NO: 65: LEFEKVFTDKFKQNFPKLQVINMQ  
 SEQ ID NO: 66: IQTHDTHEHSHEHEHHEGHFDPTWL  
 SEQ ID NO: 67: DTLIQKYFQNENLYKENLDK  
 SEQ ID NO: 68: SKLEKLKNRE  
 SEQ ID NO: 69: YFAKRYNL  
 SEQ ID NO: 70: GKEPKSKDLQK  
 SEQ ID NO: 71: LMKDKNLK  
 SEQ ID NO: 72: QNGFPENAATLAKEDAKIYK  
 SEQ ID NO: 73: DHLSYDWENELLKTADAF

Fragments of AnrP490750 (Cj0420)

SEQ ID NO: 74: FAKEYTLDKAHTDVGFKIKHLQI  
 SEQ ID NO: 75: VKGNFKDYSAVIDFDPASAEFKKLDVTI  
 SEQ ID NO: 76: SVNTENQTRDNHLQQDDFF  
 SEQ ID NO: 77: DFFKAKKYPDMTFTM  
 SEQ ID NO: 78: TFTMKKYEKIDNEKGKMT  
 SEQ ID NO: 79: GVAKGKDGEKEKIGF  
 SEQ ID NO: 80: LNGKIKRSDFKFATS  
 SEQ ID NO: 81: EVEANEK

Fragments of AnrP684299 (Cj0715)

SEQ ID NO: 82: LSATEYQLSTHV  
 SEQ ID NO: 83: ITSGQPAPKVKVELYK  
 SEQ ID NO: 84: LEANQQWKKVSEEFTEENGRIG  
 SEQ ID NO: 85: LLPYEKAENRAFG  
 SEQ ID NO: 86: KFFTKDYYTSHKINTF  
 SEQ ID NO: 87: SFELSKDQKHYHVPI  
 SEQ ID NO: 88: FGYSTYRGS

Fragments of AnrP579672 (Cj0772c)

SEQ ID NO: 89: ILEQVKPDKLEKQGYKLEIKEFTDY  
 SEQ ID NO: 90: GEADANFFQHTPYLEEFNKNKGT  
 SEQ ID NO: 91: AVYSKKYKSLLDIKE  
 SEQ ID NO: 92: IPNDPTNESRAL  
 SEQ ID NO: 93: KGLVKFKDKALKTPLDIIDNPKKIKFVELKPAQLPRLN  
 SEQ ID NO: 94: ANLNPAKDSVFIEDKESPYAN  
 SEQ ID NO: 95: GHENDPKIKALIQALQSDKIKQFIEKYN

Fragments of AnrP257863 (Cj1018c)

SEQ ID NO: 96: NGDKVSLAIIDTKGDKLESSGANRLVSQDK  
 SEQ ID NO: 97: VAEDNKIPLIAPAATGDRLLDKKIYSSRVC  
 SEQ ID NO: 98: YVFSKLNYSAVIVVQDQSTDYSLGLAKAFEKQYKSNGGQ  
 SEQ ID NO: 99: NSGDKDFRAIVAQVKSLNPEFIFLFLYYSEASLFARQSKLA  
 SEQ ID NO: 100: GYIFTDSFDANNPTTKLSKEFISVYEKAGTKEVPNFSAMG

**FIG. 4****19/20**

SEQ ID NO:101: VNEKIHQTKNYQGVS

SEQ ID NO:102: QTGNATRSVVVKEIKNQKQNYKDIIN

Fragments of AnrP108083 (Cj1380)

SEQ ID NO:103: ELNGQKQENILFTK

SEQ ID NO:104: SYAQEYEMKKFQEARENFTKNAKAVAQKETM

SEQ ID NO:105: VIALGDKNKPAl

SEQ ID NO:106: HLAQIDDELKNYQV

SEQ ID NO:107: YKEAKKAKNDKEKIAI

SEQ ID NO:108: LNKYYDANIKNYPKVSDAELKEVFSLYEKYRSL

Fragments of AnrP407676 (Cj1643)

SEQ ID NO:109: GIERPKFEDFLAGYERNKASMLN

SEQ ID NO:110: LKQPNAKLNKYVKYDPFL

SEQ ID NO:111: PTPMGDEEKLTRNDWVGIWDPNPKPYI

SEQ ID NO:112: AQNIDEKDQQLDFNSK

SEQ ID NO:113: GNRYLKHFMKYNDVY

SEQ ID NO:114: VVRENKIIYVNNVRKNPQFL

SEQ ID NO:115: PANDLRKLNEK

SEQ ID NO:116: DRGSTLYFQVLRDNMDLN

SEQ ID NO:117: AKDLSKFNLPDSKPKPKI

SEQ ID NO:118: TKIDPKSKVSNAG

SEQ ID NO:119: LIERKSTKLPLSNFN

SEQ ID NO:120:

ACE 393, ML53 (0:19)DNA

ATGAAAAAAAGTTTATTGAGTTCATGGTTGCGGTGTTGTTAAGCACAGGTTGTTGCTAAAGAATATACTTTAGA  
 TAAAGCACATACAGATGAGTTTAAATCAAACATTACAAATTAGCAATGAAAAGGAAATTCAAAGATTATTCTG  
 CGGTGATTGATTGACCTGCGAGTGCTGAATTAAAAAGCTTGTGCAACTATAAAATCGCATCTGAAATACAGAA  
 AATCAAACAAGAGATAATCACTACAGCAAGATGATTTTCAAAGCAAAAAATATCCTGATATGACTTTACAATGAA  
 AAAATATGAAAATCGATAATGAAAAGGTAATGACAGGAACCTTAACTATAGCTGGAGTTCTAAAGATATCGTTT  
 TAGATACTGAAATCGCGGTGAGCTAAAGGCAAAGATGGAAAAGAAAAATAGGCTTTCTTAAATGGAAAATCAA  
 CGCTCTGATTAAATTGCGAGCAAGTACTCAACTATTACTTTAAGTGATGATATTAATTAAATATCGAAGTTGAAGC  
 GAACGAAAAA

SEQ ID NO:121: DIVLDTEIGGVAK

SEQ ID NO:122: FAASTSTILSDDINLNIEVEANEK

SEQ ID NO:123: LDATIK

20/20

Table 1